

Call text: 14<sup>th</sup> JPIAMR transnational call for research projects within the ERA-NET JPIAMR-ACTION

## “Disrupting drug Resistance Using Innovative Design”

Short title: DRUID

**Important note to applicants:** Applications to JPIAMR joint transnational calls can require the submission of additional information on national funding platforms. All applicants must have fulfilled both joint and national requirements for an application to be eligible. Please read the national requirements in Annex B to ensure your application is eligible.

Antimicrobial resistance (AMR) affects humans, animals and plants and does not recognise geographic borders or species barriers. Progress on AMR is necessary to achieve the United Nations (UN) Sustainable Development Goals (SDGs), with AMR being deeply rooted into attainment of SDGs promoting no poverty, good health and wellbeing, zero hunger, reduced inequality and decent work and international growth. The European One Health Action Plan against AMR<sup>1</sup> encourages the EU and its Member States to deliver innovative, effective and sustainable responses to AMR, especially to reduce the emergence and spread of AMR inside and outside the EU. In line with those objectives, the Joint Programming Initiative JPIAMR engages 28 nations to curb antimicrobial resistance (AMR) with a One Health approach.

This call for research projects, developed under the ERA-Net JPIAMR-ACTION, is the 14<sup>th</sup> JPIAMR transnational call. Declining effectiveness of existing antimicrobials together with the low and insufficient number of promising new antimicrobials in the pipeline stresses the urgency to develop new protocols and innovative approaches for effective delivery and use of the already existing antimicrobials. This call will support research into therapeutic/agricultural interventions based on the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents to treat bacterial or fungal infections in One Health settings.

### 1. Aim of the call

The DRUID Call aims to improve the **treatment** of **bacterial** and **fungal** infections (including co-infection) and/or the **prevention** of the emergence/spread of resistance in **humans, animals** or

---

<sup>1</sup> [https://ec.europa.eu/health/sites/health/files/antimicrobial\\_resistance/docs/amr\\_2017\\_action-plan.pdf](https://ec.europa.eu/health/sites/health/files/antimicrobial_resistance/docs/amr_2017_action-plan.pdf)

**plants** through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

### **1.1 Topics of the call**

Your proposal should focus **on licenced antimicrobial agents (antibiotics/antifungals) or agents under pre-clinical and/or early clinical development**, and should address at least one of the following topics:

- Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation)
- Drug/plant protection agent repurposing;
- Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
- Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
- Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.

Your proposal can include the development of new mathematical models, optimisation of antimicrobial combinations and/or conditions for clinical/agricultural use, or treatment protocols based on combination therapy, personalised medicine and PK/PD. Studies may include companion diagnostics in the optimisation of treatment strategies.

The new delivery strategies should minimize impact to commensal organisms and/or the environment.

Companies are highly welcome to apply to this call by requesting funding or by using their own funding. **The eligibility of companies may depend on their funding organisation.** Please check the National Rules and Requirements (Annex B) to see the eligibility for funding.

The following sub-topics are **out of scope** of the call:

- Antiviral and antiparasitic agents
- Discovery and/or screening of new compounds, new vaccines and/or new targets
- Proposals solely aiming to develop new diagnostics or new companion diagnostics (*companion diagnostics in evaluation of the antimicrobials can be examined but they should not be the main topic of the proposal.*)

### **1.2 One Health settings**

***These three One Health settings are covered by this call***

- Human Health, and/or
- Animal Health (including wild-life, livestock, fishes, and companion animals), and/or
- Plants (including trees and crops)

In the framework of this call, participants can focus their proposal on **one or more** of the One Health settings

**The eligibility of the considered One Health setting may depend on your funding organisation.** Please check the National Rules and Requirements (Annex B) to see if the One Health setting of interest (humans, animals, plants) is eligible for funding.

### **1.3 Type of studies/ experimental approaches**

- *In silico, in vitro, in vivo* and/or
- Preclinical and clinical studies in human and in all veterinary settings, and/or
- Studies in crop/plant settings, including field studies

**The eligibility of the considered experimental approach may depend on your funding organisation.** Please check the National Rules and Requirements (Annex B) to see if your experimental approach is eligible for funding.

Participation of end-users of the project outcomes, such as parties implementing antimicrobial stewardship activities, is encouraged.

## **2. Application**

### **2.1 Eligibility**

Applicants must adhere to the specific regulations of their national funding organisations. The eligibility of the consortium will be approved by the Call Steering Group at both pre and full proposals stages. Therefore, each partner is strongly advised to check carefully the national eligibility rules defined by its own funding organisation, as specified in the National and Regional Requirements (see Annex B). Also see Figure 1 below, a checklist for composing an eligible consortium.

Eligibility rules for the consortia are:

- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries<sup>2</sup>).
- The consortium can include a maximum of six (6) project partners (including non-funded partners, Figure 1). The maximum number of partners can be increased to seven (7) if at least a partner from an under-represented country<sup>3</sup> (including LMICs<sup>4</sup>) or a company is included in the consortium.
- Additional National Rules and Regulations (Annex B) of funders also apply and must be respected.
- Project partners not eligible for funding (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisations) may be involved in projects if they bring their own funding. The budget of non-funded partners shall not exceed 30% of the requested total transnational project budget.


---

<sup>2</sup> <https://ec.europa.eu/research/horizon2020/index.cfm?pg=country-profiles> Note: UK is an EU country for the purpose of this call.

<sup>3</sup> LMICs, Lithuania, Poland

<sup>4</sup> LMICs can be funded by Sida. For details please consult Annex B.

- A Project partner not eligible to be funded cannot be the coordinator of a proposal and, like funded members, must accept all JPIAMR rules and guidelines.
- At both the pre- and full proposal stage, all partners, including non-funded partners, must submit a signed letter of intent along with their pre-/full proposal. In the absence of these letters, the proposal will be declared ineligible.
- Composition of the consortium should not be modified between the pre and the full proposal except for the inclusion of a new partner as described in the paragraph 2.2 (widening), in case of force majeure/unforeseen event (lab relocation, prolonged absence of the PI,...), or upon request of the Call Steering Group . In all cases, changes in the composition of the consortium must be approved by the Call Steering Group ahead of the submission of the full proposal.



**Figure 1.** Consortium eligibility checklist

## 2.2. Widening

In order to promote inclusiveness and ensure global participation, relevance and impact of the submitted projects in and outside Europe, the Joint Call will implement widening mechanisms before the evaluation of the full proposals:

- **At the pre-proposal stage**, the widening mechanism will apply to under-represented countries listed in footnote 3 in section 2.1. Consortia including a research team from an under-represented country can increase the total number of partners of the consortium to the maximum of seven (7).
- **At the full proposal stage**, the widening mechanism will be restricted to non-funded partners and partners supported by under-subscribed organisations, i.e. funding organisations that will most likely not use the budgets they committed to the call. The Call Steering Group will decide on the final list of under-subscribed organisations after the evaluation of pre-proposals. Consortia which are invited to the second stage of the call and which consist of fewer than seven (7) members (being the maximum) can increase the initial size of their consortia **by adding one new partner** eligible for funding by an under-subscribed organisation from the list **or** by adding one new partner not requesting funding. Consortium coordinators will be notified of this option in their invitation letter to submit a full proposal.

The teams eligible for funding by under-subscribed organisations will be able to publish their expressions of interest in the online Partner Search Tool (PST). The JCS and the under-subscribed organisations will promote the use of the PST for widening, but coordinators will be free to also invite new partners who are not registered in the tool. In any case, new partners can only join consortia after their respective under-subscribed organisation confirms that they are indeed eligible according to the national regulations. The under-subscribed organisations will inform the JCS of all new partners cleared to join at the full proposal stage.

### **2.3 Submission of joint transnational proposal**

Submissions of proposals will take place in two steps; a pre-proposal and a full proposal phase. In both cases, one joint proposal document (in English, and using the provided template) shall be prepared by the project participants of a joint transnational proposal. The pre-proposal must be submitted by the coordinator before March 8<sup>th</sup>, 2022, 14h CET using the [electronic submission platform](#) available on the JPIAMR website.

*In addition, some funding organisations may require the submission of other documents at the national level - either at the first and/or second step. Details can be found in Annex B.*

The two-step application process (pre-proposal, full proposal) will have the following targeted timetable:

November 18, 2021	Pre-announcement of the Call at Antibiotic Awareness Day 2021
January 11, 2022	Publication of the Call
January 25, 2022	Interactive webinar presentation of the Call and partner search tool.
March 8, 2022	Submission deadline for pre-proposals

May 24, 2022	Full proposal invitations sent to project coordinators
July 5, 2022	Submission deadline for full proposals
September 29, 2022	Final funding decision taken by the participating funding organisations
October 2022	Ethical Evaluation of the selected proposals
November 2022	Final funding decision announced to applicants
November 18 <sup>th</sup> , 2022	Publication of results: Antibiotic Awareness Day 2022
	Start of funding

#### **2.4 Financial modalities and funding prerequisites**

Funding is granted for a maximum of three years in accordance with national regulations and applicable legal provisions. Applicants must comply with their own specific national regulations and scientific remits as detailed in the National and Regional Requirements or specific regulations of their corresponding funding organisation (see Annex B).

The financial indicative commitments made by the funding organisations are listed in the table below. Each country will fund its own approved project partners.

#### **Anticipated indicative funding provided by each funding organisation**

<i>Country</i>	<i>Name of Organisation</i>	<i>Acronym</i>	<i>Contribution (M€)</i>
Belgium	Fonds voor Wetenschappelijk onderzoek-Vlaanderen	FWO	0,35
Belgium	Fonds de la Recherche Scientifique	FNRS	0,2
Canada	Canadian Institutes of Health Research	CIHR	0,9 CAD\$ (approx. 600K€)
Czech Republic	Ministry of Education, Youth and Sports	MEYS	0,5
Denmark	Innovation Fund Denmark	IFD	1,0
Estonia	Estonian Research Council	ETAg	0,1
France	Agence Nationale de la Recherche	ANR	2
Germany	Federal Ministry of Education and Research	BMBF	2
Hungary	National Research, Development and Innovation Office	NKFIH	0,3
Israel	Chief Scientist Office, Ministry of Health	CSO-MOH	0,3
Italy	Fondazione Regionale per la Ricerca Biomedica	FRRB	1,5
Italy	Ministero della Salute	It-MoH	0,5

Latvia	Valsts Izglitības Attīstības Agentūra / Latvijas Zinātnes padome (LZP)	VIAA/ LZP	0,6
Lithuania	Research Council of Lithuania	LMT	0,2
Moldova	Agentia Nationala Pentru Cercetare Si Dezvoltare	ANCD	0,2
Poland	Narodowe Centrum Nauki	NCN	0,5
Poland	National Centre for Research and Development	NCBR	0,6
Spain	Agencia Estatal de Investigacion	AEI	0,8
Spain	Instituto de Salud Carlos III	ISCIII	1
Sweden	Swedish Research Council	SRC	15 MSEK (approx. 1,4 M€)
Sweden	Swedish International Development Cooperation Agency	Sida	1
Sweden	The Sweden's innovation agency	Vinnova	9 MSEK (approx. 0,9 M€)
Switzerland	Swiss National Science Foundation	SNSF	0,6 MCHF (approx. 0,56 M€)
United Kingdom	Medical Research Council	MRC	£1.56M (approx. €1.8M)
United Kingdom	Biotechnology and Biological Sciences Research Council	BBSRC	
United Kingdom	Engineering and Physical Sciences Research Council	EPSRC	

### 2.5 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat (JCS) (French National Research Agency, [JPI-AMRCalls@agencerecherche.fr](mailto:JPI-AMRCalls@agencerecherche.fr)) and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to other participants. Each funding organisation has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

Please note that country-specific requirements might apply to this call. Compliance with the national or institutional regulations specified in Annex B is mandatory. Applicants are strongly advised to contact their national funding organisation (see Annex A) prior to submitting a pre-proposal.

### 3. Evaluation

International experts will perform a remote written evaluation of the proposals (minimum of two experts at the pre-proposal stage and three at the full proposal stage). Following the remote evaluation, the international experts will meet, agree on a consensus evaluation of the proposals and recommend the pre-proposals that should be invited to submit a full proposal or the full proposals that can be recommended for funding depending on the evaluation stage.

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below).

A scoring system from zero (0) to five (5) will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

**Scoring system:**

**0: Failure.** The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

**1: Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**2: Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**3: Good.** The proposal addresses the criterion in question well but certain improvements are necessary.

**4: Very good.** The proposal addresses the criterion very well, but small improvements are possible.

**5: Excellent.** The proposal successfully addresses all aspects of the criterion in question, there are no suggestions for improvement.

**Evaluation criteria proposals:**

**1. Excellence**

Criterion	For pre-proposal	For full proposal
a. Fit to the scope of the call.	X	X
b. Clarity and pertinence of the objectives.	X	X
c. Credibility of the proposed approach and methodology, in relation to the research objectives.	X	X
d. Soundness and research base of the concept.	X	X
e. Novelty, ambition, timeliness, and innovation.	X	X
f. Excellence of the consortium	X	X

**2. Impact**

Criterion	For pre-proposal	For full proposal
a. Impact of the proposal to improve the treatment of bacterial and fungal infections. Justification of the choice of pathogen should be robust and demonstrate strength of need.	X	X
b. Potential of the expected results for clinical, public health, and animal health, agriculture, or environmental benefit.	X	X
c. Potential for fostering a longer term international network of researchers. For example, bringing together specific know-how and/or innovative technologies, gathering a critical mass of patients or biological material, sharing of resources (models, databases, biobanks, etc.), and international comparisons.	X	X
d. Potential reach of the project results, including dissemination and communication measures. Accessibility of the proposed innovative strategy (different geographical areas, different populations..)		X
e. Appropriateness of end user and stakeholder participation/engagement, for example, policy makers, industry, patient organisation, health and veterinary care, farmers etc.		X

**3. Quality and efficiency of the implementation**

Criterion	For pre-proposal	For full proposal
-----------	------------------	-------------------



a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks within the given timeframe.	X	X
b. Adequate distribution of the tasks between the project partners considering the needed expertise	X	X
c. Strength of the transnational collaboration (balanced geographical distribution of the tasks)	X	X
d. Social and gender equity, cultural sensitivity and economic viability of the project consortium and research proposal, including integrating demographic and socioeconomic factors where appropriate.	X	X
e. Quality of the proposed Open Science practices, data management, Intellectual Property management, and Freedom to Operate where appropriate.		X
f. Appropriateness of the management and governance structures and procedures, including risk and innovation management.		X
g. Potential exploitation (including strategy to identify and address potential barriers) and relevance of the outcomes of the findings beyond the current project. (long term strategy)		X
h. Contingency plan, including risk assessment and mitigation (including of unforeseen circumstances like Covid-19).		X
i. Justification of the requested budget and cost-effectiveness of the project (appropriate distribution of resources in relation to project's activities, partner responsibilities and time frame).		X

Evaluation scores will be awarded for the three main criteria, and not singularly for the different aspects listed below the criteria, although these different aspects will be taken into account in scoring the main criteria. In order for an application to be considered fundable, the threshold score for individual criteria is set at three (3) (of a maximum of five (5)). The overall threshold for the score for all three criteria together is set at nine (9). The maximum score that can be reached from all three criteria together is 15 points.

### **Ethics and legal requirements**

Proposals selected for funding will undergo an ethics review by an Ethics Panel. At the full proposal stage, in addition to the scientific content and if relevant, a full description of stakeholder engagement (or a justification if this is not applicable), safety, animal studies, genetically modified organisms and microorganisms, environmental hazards and waste handling, data management, statistical methods, ethics and legal issues will be required. Applicants should anticipate this requirement, and ensure that they have consulted with relevant experts to verify the feasibility of the project, and that the proposal can be completed within the defined budget and within the prescribed time window. In the full proposal template a self-assessment checklist will need to be completed.

Each funded consortium must have all necessary ethics approvals for research on animals, and/or research involving human subjects or data/samples obtained from human subjects according to national/regional law and regulation and in compliance with EU Horizon 2020 rules before initiation of such research. Applications for ethics approval and ethics approvals should be made available immediately to the JPIAMR secretariat upon request. JPIAMR may perform an ethics review of the research at any time (evaluation and/or follow-up of the funded projects).

Project coordinators must inform the JPIAMR secretariat as well as the funders supporting the project if ethics approvals are denied. The notification should be communicated no more than 2 weeks after the rejection and the proposed rescue plan (new request for ethics approval,

modification of the workplan/ project scope) must be approved by the funders supporting the project.

Any partner of a consortium in breach of research ethics regulation will subject the whole project for re-evaluation by all funding organisations of the project resulting in potential inhibition of all activities, withdrawal of funds, cancelling of contracts, and /or legal action or other sanctions according to national law.

#### **Social and gender equity, cultural sensitivity and economic viability**

It is important that consortia and research proposals are founded upon principles of social and gender equity, cultural sensitivity and economic viability. Consortia are highly encouraged to apply these principles to the composition, leadership and management of research projects. Especially where LMICs are involved in the proposal, the impact to improving health and wellbeing should be considered.

Where relevant, research projects are expected to apply an intersectional and multi-dimensional approach by integrating sex, gender and other individual and population-level determinants of health (such as age, socio-economic status, ethnicity, religion, class, caste, and other factors) into the project's design, implementation, monitoring, evaluation and knowledge translation activities.

Research projects are expected to consider individual and population-level determinants of health when collecting and analysing data to design and/or implement interventions in ways that are accessible and affordable to target beneficiaries, to systematically capture and report on sex, gender, and other relevant factors in the project research outputs, and to meaningfully engage the participation of targeted marginalised groups in the research activities.

#### **4. Decision of project to be funded**

After peer review of the pre-proposals, selected consortia will be invited by e-mail from the JCS to submit a full proposal. The final funding decision will be taken by the Call Steering Group based on the review and the recommendation by the Peer Review Panel, and will be subject to budgetary considerations and ethical review.

#### **5. Reporting requirements and other obligations of JPIAMR grantees**

Overall project monitoring will be the responsibility of the JPIAMR secretariat. On behalf of the project consortium, the coordinator is required to submit reports to JPIAMR according to the Monitoring policy for JPIAMR funded projects and networks. The following must be submitted:

- A mid-term Report, on behalf of the consortium, 18 months after the project start.
- A final report on the consortium, on behalf of the consortium, within 2 months of the end of the consortium.
- An ex-post report three years after the closure of the consortium.

The monitoring outcomes will be collected and made accessible to all funding organisations. In addition, the monitoring of each funded project may also be done through review seminars.

The JPIAMR secretariat will contact the coordinator one month in advance of reporting deadlines and provide them with a link to the JPIAMR reporting system.

Outside of the above-listed reports, Grantees have an obligation to supply the JPIAMR with updated information of the consortium and its results, if requested.

In addition to these central reporting obligations, each research team will be requested to comply with the reporting rules of its national funding organisation. In accordance with those specific national/regional or institutional regulations, each participant may also be required to submit periodical and final financial and research reports to their funding organisations (See Country-specific information in Annex B).

## **6. Intellectual Property**

The ultimate goal of Joint Programming is to bring together national research efforts in order to make better use of public R&D resources and to tackle common global challenges more effectively in selected key areas.

For Joint Programming activities to contribute effectively to socioeconomic progress, the results of the research activities must be exploited. This requires appropriate identification and protection of the intellectual property being generated and effective knowledge transfer. Any particular protection and exploitation strategy should be agreed before the research activities start. The ten principles of [Socially Responsible Licensing](#) (SRL) should be part of this strategy.

Depending on the nature of the research and on the interests of the different parties, if there are opportunities for exploitation, it is recommended that parties decide in advance on either adopting a common exploitation strategy or leaving exploitation of results to the party best placed to commercialise it, with appropriate compensation mechanisms for the contributing parties. Please see section 7 for a link to a simplified consortium agreement template, available on the DESCA website. National rules and regulations may apply, please consult Annex B.

## **7. Consortium Agreement**

The consortium partners of each funded project are required to set up and sign a consortium agreement (CA) in order to deal with any other issues related to the role, tasks and responsibilities within the consortium, the protection of intellectual property, and where applicable how the consortium will address the ten principles of [SRL](#). The CA needs to be in accordance with the national funding rules of the respective funding organisations - see Annex B. Upon request, this consortium agreement must be made available to the concerned funding organisations.

The CA must address (as a minimum), the following points:

- common start date and duration of the research project;
- organisation and management of the project;
- role, tasks, and responsibilities of each partner;
- the resources and funding;
- confidentiality and publishing;
- Intellectual Property Rights (if applicable);
- how the ten principles of Socially Responsible Licensing will be addressed (if applicable);
- decision making within the consortium;
- handling of internal disputes;
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding organisations and the JPIAMR secretariat.

Please see the [DESCA website](#) for further information on the development of a simplified consortium agreement under the Horizon 2020 Framework.

## **8. Open access and FAIR data**

Following the ambitions of open access, researchers involved in JPIAMR funded projects must ensure that science and society can be made aware of the information about the project as early as possible in the research process.

In cases where there is information that cannot be shared (either by open access publication, or by sharing of data or biological materials), this must be explained, and substantiated in the JPIAMR reporting (e.g. temporary confidentiality may be accepted in the case of commercial exploitation).

### Publications (open access):

Unless it goes against their legitimate interests, each beneficiary must — as soon as possible — disseminate its results by disclosing them to the public by appropriate means (other than those resulting from protecting or exploiting the results), including in scientific publications (in any medium).

The JPIAMR promotes Green, Diamond and Gold Open Access measures, as recommended by the EC Recommendation on Open Access policies for Member States (17<sup>th</sup> July 2012), towards Horizon 2020. Each participant may also be required to comply with the Open Access policy of its funding organisation (See country-specific information in Annex B).

In the context of the JPIAMR, the following policy applies:

- Publishing costs in an open access context, related to scientific results obtained in the context of a JPIAMR project, should, in principle, be considered eligible. National funding regulations may apply (see country-specific requirements in Annex B).
- Authors are encouraged to retain their copyright or, in case of transfer of copyright to third parties, at least to retain the right to disseminate via open access. National funding regulations may apply (see country-specific requirements in Annex B).

### Research data (FAIR):

JPIAMR requires grant holders to make their data as much as possible Findable, Accessible, Interoperable, and Reusable (FAIR). FAIR data may also be open data, however, restricted access to FAIR data is also possible. FAIR data allow researchers to verify research results and reuse data in future research. FAIR research data can typically be accessed, mined, exploited, reproduced and disseminated: under certain conditions, or free of charge for the user (=open). Also biological materials (biospecimens, microbial strains/samples, molecular derivatives) need to be FAIR. This may be done by describing the biomaterials with metadata (and these are digital).

In the context of the JPIAMR, the following policy applies:

- JPIAMR expects researchers to create reusable research data and biological materials, and to maximize the opportunities to make the research data generated from their scientific work available.
- In case that data originates from ongoing projects, the funding conditions related to those projects needs to be taken into account. These conditions cannot be overruled by conditions for new projects.
- At the end of the project, the consortium needs to provide information on how the data and/or biological materials can be found (e.g. catalogue), where they are stored

(repository), the conditions for access or use to the resources (e.g. open or restricted access).

What needs to be done in the application phase?

- Check the requirements for data management and data sharing of the relevant national funder;
- Plan the collection of research data, and biomaterials. Start planning a DMP (data management plan); consult a data expert; look for services from research infrastructures.
- Search for reusable data and biomaterials; ask for permission to use these.
- Take costs for data management and infrastructure into account when planning the budget.

Further information can be found at the JPIAMR website.

The Science Europe 'Practical Guide to the International Alignment of research Data Management' with (1) core requirements for data management, allowing funders and research institutes to align their RDM requirements and template; (2) criteria for the selection of trustworthy repositories for storing and sharing research data.

[https://www.scienceeurope.org/media/jezkhnoo/se\\_rdm\\_practical\\_guide\\_final.pdf](https://www.scienceeurope.org/media/jezkhnoo/se_rdm_practical_guide_final.pdf)

The Horizon 2020 Guidelines with indications on how researchers can comply with their responsibilities regarding research data quality, sharing and security:

'Guidelines on Open Access to Scientific Publications and Research Data in Horizon 2020'

[http://ec.europa.eu/research/participants/data/ref/h2020/grants\\_manual/hi/oa\\_pilot/h2020-hi-oa-pilot-guide\\_en.pdf](http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-pilot-guide_en.pdf)

The BBMRI services for ethical, legal and societal issues (ELSI) <http://www.bbMRI-eric.eu/services/common-service-elsi/>

## 9. General Data Protection Regulation (GDPR)

By submitting an application, the applicants consent to the use, processing and retention of their personal data<sup>[1]</sup>, in accordance with article 6.1 (e) and (c) of the General Data Protection Regulation (GDPR) (2016/679) and for the purposes of:

- processing and evaluating the application where processing shall be lawful only if and to the extent that processing is necessary for the performance of a task carried out in the public interest or in the exercise of official authority vested in the controller;
- administering any subsequent funding award;
- managing the relationship between the applicant and the Funding Organisations ;
- analysing and evaluating the call;
- providing aggregate data to national and European surveys and analyses on the funded projects;

---

<sup>[1]</sup> Last name, first name of the researchers, date of birth, professional contact information, degree(s), position (current and previous), fields of activity, place of work, organisation, address(es), curriculum vitae, ORCID number, name and reference of projects, pre-proposals, project proposals (scientific document, administrative and financial appendix).

- and complying with audits that may be initiated by the Funding Organisations and the European Commission (or its agencies).

In addition, by submitting an application, the applicants agree to share their personal data<sup>[1]</sup> with funders based outside the European Economic Area and with third parties such as evaluators (some of which may be based outside the European Economic Area) in relation to the above activities.

Funders and third parties may link the data that applicants provide in the application with national, bibliographic or external research funding data which is available through public subscription based databases (e.g. Scopus, Web of Science, etc.) or other national / open datasets.

## **10. Privacy**

Responding to a JPIAMR call for proposals, both as coordinator or partner, gives JPIAMR and associated funding organisations the right to use and store the information submitted for analysis of the call success rate, national response rate, etc. Information will only be shared between the associated funding organisations and the JPIAMR secretariat, except for consortia including partners applying for funding from a Swedish Funder (SRC or Sida). For those consortia, the applications (pre and full proposals) may be made available upon request after the publication of the funding decision. No individual/private data will be published.

Accepting a JPIAMR grant award and associated grant contract from a national funding organisation gives JPIAMR and associated funding organisations the right to store, share, and analyse information on beneficiaries and consortia (rules may differ between different countries). Composition of the awarded consortia (Principal investigators, Institution) as well as the title, acronym and abstract of funded projects will be published and openly accessible. No data will be shared with third parties or commercial entities without the formal consent of the project coordinators, except for consortia including partners applying for funding from a Swedish Funder (SRC or Sida). For those consortia, the applications (pre and full proposals) may be made available upon request after the publication of the funding decision.

## **11. Acknowledgements**

All results disseminated by the funded projects (in any form, including electronic) should acknowledge funding from the JPIAMR and include the following text: *This project (project acronym/name) has been supported by (name of the national funder) under the framework of the JPIAMR - Joint Programming Initiative on Antimicrobial Resistance.*

## Annex A: National contact persons for each party providing funding

Country	Funding org.	Contact person(s)	Email	Telephone
Belgium	FWO	Toon Monbaliu	<a href="mailto:eranet@fwo.be">eranet@fwo.be</a>	+32 (0)2 550 15 70
Belgium	FNRS	Florence Quist Joël Groeneveld	<a href="mailto:international@frs-fnrs.be">international@frs-fnrs.be</a>	+32 (0)2 504 93 51 +32 (0)2 504 92 70
Canada	CIHR	Contact Centre	<a href="mailto:support-soutien@cihr-irsc.gc.ca">support-soutien@cihr-irsc.gc.ca</a>	+1 613.954.1968
Czech Republic	MEYS	Daniel Hanspach	<a href="mailto:Daniel.Hanspach@msmt.cz">Daniel.Hanspach@msmt.cz</a>	+420 234 811 360
Denmark	IFD	Martin Kyvsgaard International Investment Officer  Marlene Fredborg Investment Officer  International Collaborations	<a href="mailto:Martin.kyvsgaard@innofond.dk">Martin.kyvsgaard@innofond.dk</a>  <a href="mailto:Marlene.fredborg@innofond.dk">Marlene.fredborg@innofond.dk</a>  <a href="mailto:internationale@innofond.dk">internationale@innofond.dk</a>	+45 61905081  +45 61905052
Estonia	ETAg	Argo Soon Margit Suuroja	<a href="mailto:argo.soon@etag.ee">argo.soon@etag.ee</a> <a href="mailto:margit.suuroja@etag.ee">margit.suuroja@etag.ee</a>	+372 730 0372 +372 731 7360
France	ANR	Séverine Olivier Ingrid Pfeifer Sophie Gay	<a href="mailto:JPI-AMRCalls@agencerecherche.fr">JPI-AMRCalls@agencerecherche.fr</a>	+33 1 73 54 81 74 +33 1 78 09 80 22 +33 1 78 09 80 39
Germany	DLR	Barbara Junker Akin Akkoyun	<a href="mailto:Barbara.junker@dlr.de">Barbara.junker@dlr.de</a> <a href="mailto:Akin.akkoyun@dlr.de">Akin.akkoyun@dlr.de</a>	+49 228 3821 1274 +49 228 3821 1864
Hungary	NKFIH	Dr. Klára Horváth	<a href="mailto:klara.horvath@nkfi.gov.hu">klara.horvath@nkfi.gov.hu</a>	+36 18963748
Israel	CSO-MOH	Ronit Meyuhas Irit Allon	<a href="mailto:Ronit.meyuhas@moh.gov.il">Ronit.meyuhas@moh.gov.il</a> <a href="mailto:Irit.allon@moh.gov.il">Irit.allon@moh.gov.il</a>	+97225082159 +97225082167
Italy	FRRB	Paola Bello, Carmen De Francesco Giusi Caldieri	<a href="mailto:progetti@frrb.it">progetti@frrb.it</a>	+ 39 02 67650174
Italy	It-MoH	Maria Josè Ruiz Alvarez Chiara Ciccarelli	<a href="mailto:mj.ruizalvarez-esterno@sanita.it">mj.ruizalvarez-esterno@sanita.it</a> <a href="mailto:c.ciccarelli@sanita.it">c.ciccarelli@sanita.it</a>	+39 06 5994 3214 +39 06 4990 6836 +39 06 59943919
Latvia	VIAA LZP	Uldis Berkis Arnis Kokorēvičs	<a href="mailto:Uldis.Berkis@viaa.gov.lv">Uldis.Berkis@viaa.gov.lv</a> <a href="mailto:arnis.kokorevics@lzp.gov.lv">arnis.kokorevics@lzp.gov.lv</a>	+371-29472349 +371-29473753
Lithuania	LMT	Živilė Ruželė	<a href="mailto:Zivile.ruzele@lmt.lt">Zivile.ruzele@lmt.lt</a>	+37067614383
Moldova	ANCD	Vadim Iatchevici Olga Davidenco	<a href="mailto:vadim.iatchevici@ancd.gov.md">vadim.iatchevici@ancd.gov.md</a> <a href="mailto:olga.davidenco@ancd.gov.md">olga.davidenco@ancd.gov.md</a>	+373 22 270-445
Poland	NCN	Monika Pobiega Jolanta Palowska	<a href="mailto:monika.pobiega@ncn.gov.pl">monika.pobiega@ncn.gov.pl</a> <a href="mailto:jolanta.palowska@ncn.gov.pl">jolanta.palowska@ncn.gov.pl</a>	+48 123419176 +48 695211478

Poland	NCBR	Marcin Chmielewski	<a href="mailto:marcin.chmielewski@ncbr.gov.pl">marcin.chmielewski@ncbr.gov.pl</a>	+48 22 39 07 109 +48 571 226 666
Spain	AEI	Jesús Sanz Esther Chacón	<a href="mailto:amr@aei.gob.es">amr@aei.gob.es</a> <a href="mailto:esther.chacon@aei.gob.es">esther.chacon@aei.gob.es</a>	+34 916037105
Spain	ISCIII	Cándida Sanchez Barco	<a href="mailto:cbarco@isciii.es">cbarco@isciii.es</a>	+34 918222063
Sweden	SRC	Kristian Haller	<a href="mailto:Kristian.haller@vr.se">Kristian.haller@vr.se</a>	+46 8 546 12 307
Sweden	Sida	Markus Moll	<a href="mailto:Markus.Moll@sida.se">Markus.Moll@sida.se</a>	+46721434246
Sweden	Vinnova	Malin Eklund Pontus von Bahr	<a href="mailto:malin.eklund@vinnova.se">malin.eklund@vinnova.se</a> <a href="mailto:pontus.vonbahr@vinnova.se">pontus.vonbahr@vinnova.se</a>	+46 8 473 32 02 +46 8 473 30 91
Switzerland	SNSF	Barbara Flückiger Schwarzenbach	<a href="mailto:barbara.flueckiger@snf.ch">barbara.flueckiger@snf.ch</a>	+41 (0)31 308 23 40
United Kingdom	UKRI: MRC BBSRC EPSRC	Carolyn Johnson Stephen Webb Matthew Weaver	<a href="mailto:Carolyn.Johnson@mrc.ukri.org">Carolyn.Johnson@mrc.ukri.org</a> <a href="mailto:Stephen.webb@bbsrc.ukri.org">Stephen.webb@bbsrc.ukri.org</a> <a href="mailto:Matthew.Weaver@epsrc.ukri.org">Matthew.Weaver@epsrc.ukri.org</a>	



## Annex B: National Rules and Requirements

Please note that this is only a summary. Refer to the national websites and contact the respective national contact persons for full details.

Belgium – FWO Fonds voor Wetenschappelijk onderzoek-Vlaanderen	
Specific National/ Regional rules	<p><b><u>Involved regional Funding Programmes:</u></b></p> <p>Both the FWO Strategic Basic Research Projects (SBO), next to the more fundamental junior/senior research projects (FO), are integrated in this call, each with their specific eligibility conditions. It is, in the light of the projects eligibility, of utmost importance to respect the appropriate regulations. For example when it comes to the <b><i>mandatory valorisation aspect for the SBO projects.</i></b></p> <p>It is consequently strongly advised to contact the FWO contact point (see Annex A), in order to verify the eligibility of the proposals and avoid ineligible projects/research consortia.</p> <p><b><u>Who is eligible for FWO funding?</u></b></p> <p>The eligibility of institutions and its researchers can be verified in the relevant regulations:</p> <p>→ For Fundamental research, <a href="#">see articles 10-12</a></p> <p>→ For Strategic Basic Research, <a href="#">see articles 4-8</a></p>
Eligible costs	<p><b><u>Minimum and/or maximum project duration:</u></b></p> <p>Projects may last up to 36 months, which implies the funding has to be budgeted and spent accordingly. Extensions are not allowed in this phase.</p> <p><b><u>Minimum and/or maximum funding per project:</u></b></p> <p>The maximum requested budget per partner amounts to 350.000 EUR (incl. overhead).</p> <p><b><i>Beware, the funding rules differ per FWO funding channel (FO and SBO):</i></b></p> <p>- <b>FO:</b> a 6% structural overhead should be calculated on the direct costs. E.g., a practical example: if the sum of all project costs (personnel, consumables, travel, etc.) amount to 300.000 EUR, then the overhead will amount to 18.000 EUR (6% of 300.000 EUR) and the total requested cost 318.000 EUR. This total requested cost may never exceed 350.000 EUR.</p> <p>- <b>SBO:</b> The <a href="#">SBO cost model</a> applies. However, in this framework, and following a similar method like the fundamental projects (FO), an overhead rate has to be applied on the project costs. SBO overhead can go up to 17% and is determined by the researchers' host institution.</p>
Additional documents required	<p><b>When the FWO SBO project channel is chosen, the researchers are asked to provide proactively, and before the pre-proposal submission deadline, a concise – but to the point – valorisation plan to the FWO</b> (no fixed format, max. 1-2 A4-pages), which i) clarifies the valorisation context within Flanders (and also internationally preferably), and ii) mentions the involved – and specific - actors from Flanders. This document can be sent towards the <a href="mailto:eranet@fwo.be">eranet@fwo.be</a> email address. <b>Failure to comply with this requirement can lead to ineligibility.</b></p>
Eligible One Health settings	<p>All health settings are eligible, if the type of research fits the appropriate FWO funding channels' scope.</p>

<b>Eligible experimental approaches</b>	The FWO can go up to 'pre-clinical' research. As such <b>clinical studies are not eligible</b> for funding by the FWO.
<b>Further information</b>	<ul style="list-style-type: none"> <li>- Participation in this call does not interfere with the 'regular' project submission framework at national level, and is consequently not taken into account for calculating the max. available number of new applications and running projects combined. However, <b>researchers can only participate within 2 different international consortia in this call.</b></li> <li>- Projects aiming at the development of a spin-off company are not eligible in this context.</li> <li>- The project duration is limited to 36 months, which implies the funding has to be budgeted and spent accordingly. An automatic prolongation and using positive (financial) balances after the end date is not applicable in this framework. As such article 28 of the <a href="#">FWO Research Projects</a> and article 14 of the <a href="#">Strategic Basic Research (SBO)</a> regulations do not apply in this context.</li> <li>- The PI, for each of the participating institutions applying for FWO funds, must hold an appointment that fully covers the duration of the research project.</li> </ul>

<b>Belgium – FNRS Fonds de la Recherche Scientifique</b>	
<b>Specific National/Regional rules</b>	<ul style="list-style-type: none"> <li>• All eligibility rules and criteria can be found in the <a href="#">PINT-Multi regulations</a></li> </ul>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>• All eligibility rules and criteria can be found in the <a href="#">PINT-MULTI regulations</a></li> <li>• <b>“Overhead” is not an eligible cost.</b> If the project is selected for funding, these costs will be subject to a separate agreement between the institution of the beneficiary and the F.R.S.-FNRS.</li> </ul>
<b>Additional documents required</b>	<b>Applicants to F.R.S.-FNRS funding must provide basic administrative data by submitting an administrative application on e-space within 5 working days after the general deadline of JPIAMR action to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application. Proposals invited to the second stage will be able to complete the pre-proposal form and provide information for the full proposal upon validation by the F.R.S.-FNRS.</b>
<b>Eligible One Health settings</b>	All 3 research areas (Human Health, Animal Health and Environement) are eligible for funding.
<b>Eligible experimental approaches</b>	Clinical studies are <b>not</b> eligible for funding by the F.R.S.-FNRS
<b>Further information</b>	<p>Additional national eligibility criteria for the proposal beyond the general criteria of the joint call</p> <ul style="list-style-type: none"> <li>• Basic research (low Technology Readiness Level) carried out in a research institution from the “Fédération Wallonie-Bruxelles”</li> <li>• The F.R.S.-FNRS will not fund clinical research</li> </ul> <p>The F.R.S.-FNRS will not fund industrial partners or any activity related to the private sector</p>

--	--

Canada – CIHR Canadian Institutes of Health Research	
Specific National/ Regional rules	<ul style="list-style-type: none"> <li>• Categories of individuals eligible to apply for CIHR grants include, but are not limited to, researchers, knowledge users, scholars, health professionals, undergraduates, graduate students, and postdoctoral scholars.</li> <li>• Among eligible organisations that CIHR may fund are non-governmental organisations with a research or knowledge translation mandate. Details regarding eligible applicants for a given competition will be specified in the funding opportunity on <a href="#">ResearchNet</a>.</li> <li>• The Nominated Principal Applicant must be an <a href="#">independent researcher</a> and must be affiliated with a Canadian postsecondary institution and/or their affiliated institutions; individuals working with municipal, provincial, and/or territorial governments are also eligible where the research proposed is not already funded by that Government of Canada sector.</li> <li>• Individuals in the Nominated Principal Applicant role must have their substantive role in Canada for the duration of the requested grant term.</li> <li>• Appointments and/or positions that can be renewed prior to the end of the requested grant term are eligible at the discretion of the administering institution.</li> <li>• CIHR grants and awards are paid to <a href="#">CIHR-eligible institutions</a>, through a CIHR account, from which the Nominated Principal Applicant draws funds.</li> <li>• Canadian applicants must complete a CIHR application and submit it using <a href="#">ResearchNet</a> in addition to the proposal submitted to the <a href="#">Joint Call Secretariat</a>.</li> <li>• Canadian applicants must submit an Operating Budget for the project, with the amounts quoted in <b>Canadian dollars</b>, and a complete justification for funds requested using <a href="#">ResearchNet</a> in addition to the proposal submitted to the <a href="#">Joint Call Secretariat</a>. The deadline for submission of this application is the same as the proposal deadline to the Joint Call Secretariat.</li> <li>• Projects receiving a CIHR grant must comply fully with the <a href="#">CIHR Funding Policies</a>. Policies and guidelines cover areas such as Applicant Responsibilities, Official Languages policy, Access to Information and Privacy Acts. For more information, please refer to <a href="#">Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2)</a> and <a href="#">Tri-Agency Framework: Responsible Conduct of Research</a>.</li> <li>• To complete the ResearchNet application for funding you must include your personal information. CIHR will collect, use, retain and dispose of your personal information in accordance with the <i>Access to Information and Privacy Act</i>. If applicable, the information provided may be shared, in whole or in part, with CIHR Institute Staff. CIHR will not share the information collected through your abbreviated application in CIHR ResearchNet with other institutions or signatories to the JPIAMR.</li> <li>• Funding applications submitted to JPIAMR will be held in jurisdictions outside of Canada and will not be subject to the provisions of the <i>Privacy Act</i>. Information submitted to JPIAMR as part of the applications will be governed by the provisions of EU data protection laws, the European Data Protection Regulation (GDPR). Please note that all parties on applications must also comply with (GDPR) (2016/679).</li> </ul>

	Canadian applicants do NOT need to submit the pre-proposal through CIHR ResearchNet. ONLY the full proposal.
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>Applicants should review the Use of Grant Funds Section of the Tri-Agency (CIHR, NSERC and SSHRC) <a href="#">Guide on Financial Administration</a> for a complete listing and description of allowable costs and activities.</li> </ul> <p>The costs for data management, infrastructure, data storage and data sharing is considered an eligible expense.</p>
<b>Additional documents required</b>	<ul style="list-style-type: none"> <li>Applications submitted to CIHR require applicant consent and institutional approval (if applicable) to the use and disclosure of full application and nominative information for relevance review and funding decisions at the time of application.</li> <li>The applicant must comply with all JPIAMR reporting requirements.</li> <li>The Nominated Principal Applicant will be required to submit an Electronic Final Report to CIHR. This online report will be made available to the Nominated Principal Applicant on <a href="#">ResearchNet</a> at the beginning of the grant funding period and can be filled in as the research progresses.</li> <li>All reports may be shared with partners supporting the grant.</li> <li>The Nominated Principal Applicant must have successfully completed one of the <a href="#">sex- and gender-based analysis training modules</a> available online through the CIHR Institute of Gender and Health and have submitted a Certificate of Completion (see How to Apply section). Select and complete the training module most applicable to your research project. Applicants are encouraged to review the "<a href="#">How to integrate sex and gender in research</a>" section on the CIHR website.</li> <li>CIHR is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in research, training and knowledge translation.</li> <li>CIHR adheres to the principles of equity, diversity and inclusion (EDI) with equal importance in the research design and practices as well as the research environment (team composition, leadership and management of research projects) to strengthen applications. CIHR's position on EDI is available in the <a href="#">Tri Agency Statement on Equity, Diversity and Inclusion</a>. Additional guidance can be found on the <a href="#">Best practices in Equity, Diversity and Inclusion in Research</a> webpage.</li> </ul> <p><b>Consortium Agreement</b></p> <ul style="list-style-type: none"> <li>It is incumbent upon the Canadian researchers to review and understand all expectations of this call text including the requirement for a Consortium Agreement (CA). The Consortium Agreement specifies the relationship among the funded researchers, outlines how the project will be organized and managed and includes clauses related to Intellectual Property and FAIR data.</li> <li>The Nominated Principal Applicants who are successful in this competition will be expected to develop and sign a Consortium Agreement (CA) - depending on the composed consortium, different rules apply. Please consult the relevant country National rules and requirements in this Annex and discuss with your consortium partners when a signed CA is required and plan ahead*.</li> <li>NPAs do NOT need to send a signed copy of the CA, nor a declaration of the CA to CIHR. JPIAMR will contact you directly for a copy should it be needed.</li> </ul> <p><b>* It is noted that CIHR does not retain or claim any rights to IP in relation to research that it funds. Accordingly, the Canadian researchers retain full freedom in negotiating the Consortium Agreement required, including whether or not to accept the IP conditions.</b></p>

<b>Eligible One Health settings</b>	Projects addressing human health will be eligible for funding. CIHR will NOT be funding projects on animal health and/or environment that do not include human health research activities.
<b>Eligible experimental approaches</b>	Projects involving pre-clinical and/or clinical trials are eligible under this Funding Opportunity.
<b>Further information</b>	<ul style="list-style-type: none"> <li>The total amount available for the Canadian component of successful projects is 900,000 CAD \$, enough to fund the Canadian component of up to two (2) joint transnational teams (up to 150,000 CAD \$ per year for three (3) years for a maximum of 450,000 CAD \$). The proposals will be funded based on the ranking list recommended by the Peer Review Panel and decided by the Call Steering Group. The final funding decision will be made by the national/regional funding organisations and will be subject to budgetary considerations with the goal of optimal usage of the available budget.</li> <li>Approved joint transnational teams may receive an across-the-board cut to the budget, if necessary, to maximize the number of funded opportunities.</li> </ul> <p>For full details of CIHR's requirements, please refer to the Funding Opportunity on <a href="#">ResearchNet</a>.</p>

<b>Czech Republic – MEYS Ministry of Education, Youth and Sports</b>	
<b>Specific National/Regional rules</b>	<p>The participants from the Czech Republic in the projects' consortia must meet the criteria of <b>research and knowledge-dissemination organisation</b> (hereinafter referred to as the "research organisation") in accordance with the <a href="#">Framework for State Aid for Research and Development and Innovation (2014/C 198/03)</a>. These might be public universities, public research institutes and/or another entities classified as research organisations.</p> <p>It is obligatory that the Czech participants involved in the projects' consortia prove compliance with the eligibility criteria and fulfilment of the conditions set by <b>§ 18 of the Act No. 130/2002 Coll. on Support of Research, Experimental Development and Innovation from Public Funds</b> and on Amendment to Some Related Acts by means of a <b>Statutory Declaration</b>. The required procedure is described and the Statutory Declaration template is available on the websites of the Ministry of Education, Youth and Sports</p>
<b>Eligible costs</b>	<p>Eligible costs for a Czech participant involved in a project consortium are defined by <b>§ 2 of the Act No. 130/2002 Coll. on Support of Research, Experimental Development and Innovation from Public Funds</b> and on Amendment to Some Related Acts. The maximum indirect costs set for the present call are <b>25 % (flat rate)</b> of direct costs without the sub-contracting.</p> <p>The <b>aid intensity</b> for activities carried out by a research organisation might be at the level of <b>100 %</b> provided that the research organisation complies entirely with requirements stipulated by the Article 2.1.1 "Public funding of non-economic activities" of the <a href="#">Framework for State Aid for Research and Development and Innovation (2014/C 198/03)</a> and proves it by means of the above-mentioned <b>Statutory Declaration</b>.</p> <p>Should the above-stated criteria not be fulfilled by the Czech participant, funding rates will be adjusted appropriately by the Ministry of Education, Youth and Sports and will reach the level of <b>100 % for fundamental/basic research</b> activities, <b>50 % for applied research</b> activities and <b>25 % for experimental development</b> activities.</p>

	Each Czech participant in a project consortium is requested to specify the costs related to the envisaged R&D activities in detail by using the national <b>Eligible Costs Specification</b> template available on websites of the Ministry of Education, Youth and Sports.
<b>Additional documents required</b>	All of the requested documentation for pre-proposals ( <b><u>Statutory Declaration and Eligible Costs Specification</u></b> ) shall be sent by each Czech participant in a project consortium to the Ministry of Education, Youth and Sports both by electronic correspondence and post.
<b>Eligible One Health settings</b>	No additional limitations.
<b>Eligible experimental approaches</b>	No additional limitations.
<b>Further information</b>	No additional limitations

Denmark - IFD Innovation Fund Denmark	
<b>Specific National/Regional rules</b>	<p>At least one Danish non-academia institution as co-applicant in the transnational consortium.</p> <p><b>Maximum funding per partner:</b> 300.000 EUR including overhead</p> <p><b>Maximum funding per project:</b> 500.000 EUR including overhead</p>
<b>Eligible costs</b>	<p><b>Funding rates as listed in <u><a href="#">national guidelines</a></u> section 9.</b></p> <p><b>Eligibility of a partner as a beneficiary institution:</b> Private sector (e.g. for profit companies), research centres, secondary or higher education (e.g. schools and universities), public bodies (e.g. municipalities, regional/national administrative bodies), other non-profit legal entities (e.g. NGO, stakeholder associations, societies,...)</p> <p><b>Eligibility of costs, types:</b> Personnel, subcontracting (national organisations), travel, equipment, materials, communication, other, overhead</p>
<b>Additional documents required</b>	<p>Mandatory to submit proposal and full-proposal via the E-grant system Innovation Fund Denmark will automatically register the Danish partners who will receive a notification with more information from us when completed.</p> <p>Financial and progress reporting via the E-grant system is mandatory. Please use the templates, which will be available on your projects site once you initiate a reporting session.</p>
<b>Eligible One Health settings</b>	All settings
<b>Eligible experimental approaches</b>	All approaches
<b>Further information</b>	<p><u><a href="#">Innovation Fund Denmark</a></u></p> <p><u><a href="#">National guidelines</a></u></p> <p>Martin Kyvsgaard International Investment Officer <u><a href="mailto:Martin.kyvsgaard@innofond.dk">Martin.kyvsgaard@innofond.dk</a></u></p>

	+45 61905081  Marlene Fredborg Investment Officer <a href="mailto:Marlene.fredborg@innofond.dk">Marlene.fredborg@innofond.dk</a> +45 61905052  International Collaborations <a href="mailto:internationale@innofond.dk">internationale@innofond.dk</a>
--	--

Estonia – ETAg Estonian Research Council	
<b>Specific National/ Regional rules</b>	<p>The Host Institution may be any legal entity that is registered and located in Estonia. The Host Institution must confirm to the Estonian Research Council (with a confirmation letter after the submission deadline) that the project can be carried out on their premises and that they will employ the Principal Investigator during the proposed project, should the project receive funding.</p> <p>If the Host Institution is a for-profit institution, then State aid and de minimis aid regulations must be taken into account</p> <p>The Principal Investigator:</p> <p>1.1.1. must have an updated public profile in the Estonian Research Information System (ETIS) by the submission deadline;</p> <p>1.1.2. must hold a doctoral degree or an equivalent qualification. The degree must be awarded at the latest by the submission deadline of the grant application;</p> <p>1.1.3. must have published or received formal acceptance for at least three articles that comply with the requirements of Clause 1.1 of the ETIS classification of publications, or at least five articles that comply with the requirements of Clauses 1.1, 1.2, 2.1 or 3.1, within the last five calendar years prior to the proposal submission deadline. International patents are equalled with publications specified under Clause 1.1. A monograph (ETIS Clause 2.1) is equalled with three publications specified in Clause 1.1 if the number of authors is three or fewer. If the applicant has been on pregnancy and maternity or parental leave or performed compulsory service in the Defence Forces, or has another acceptable reason, they can request the publication period requirement to be extended by the relevant period of time.</p>
<b>Eligible costs</b>	<p>2.1 Research expenses consist of direct costs, indirect costs and subcontracting costs. The research expenses must be used to carry out the project and be separately identifiable.</p> <p>2.2 Direct costs</p> <p>2.2.1 Personnel costs are monthly salaries with social security charges and all the other statutory costs of the project participants, calculated according to the person's commitment and in proportion to the person's total workload at their Host Institution.</p> <p>2.2.2 Scholarships may be paid to master's and doctoral students. Alternatively, remuneration can be paid as salary to students. All payments to the students should be done according to the usual practices of the Host Institution, following the Estonian legal acts.</p> <p>2.2.3 Travel costs may cover expenses for transport, accommodation, daily allowances and travel insurance.</p> <p>2.2.4 Other direct costs include:</p> <ul style="list-style-type: none"> <li>- consumables and minor equipment related to the project;</li> <li>- publication and dissemination of project results;</li> <li>- organising meetings, seminars or conferences (room rent, catering);</li> </ul>

	<p>- fees for participating in scientific forums, conferences and other events related to the project;</p> <p>- all other costs that are identifiable as clearly required for carrying out the project (e.g. translation, copy editing, webpage hosting, etc.).</p> <p>2.2.5 Subcontracting costs should cover only the additional or complementary research related tasks (e.g. analyses, conducting surveys, building a prototype, etc.) performed by third parties. Core project tasks should not be subcontracted. Subcontracting costs should not be included in the overhead calculation. The activities and budget should be described in the proposal. Subcontracting costs may not exceed 15% of the total requested budget.</p> <p>2.4 Indirect costs are overhead costs, which may not exceed 20% of the eligible (requested) direct research costs and should cover the general expenses of the Host Institution. Costs for equipment and services intended for public use (a copy machine or a printer that is publicly used, phone bills, copy service, etc.) should be covered from the overhead.</p> <p>2.5 Double funding of activities is not acceptable.</p>
<b>Additional documents required</b>	None
<b>Eligible Health settings</b>	All 3 research areas (Human Health, Animal Health and Plants/environnement) are eligible for funding.
<b>Eligible experimental approaches</b>	All approaches with the exception of phase III clinical trials.
<b>Further information</b>	<p>ETAg will provide 1 grant of size of 100 000 €. This amount includes overhead cost that can not exceed 20% of eligible costs. Overhead calculation must exclude cost of subcontracting.</p> <p>Guides for applicants and funding rules are available on the web-page of Estonian Research Council: <a href="https://www.etag.ee/valiskoostoo/euroopa-horisont/partnerlused/era-net-projektid/">https://www.etag.ee/valiskoostoo/euroopa-horisont/partnerlused/era-net-projektid/</a></p>

<b>France – ANR French National Research Agency</b>	
<b>Specific National/Regional rules</b>	<p>ANR may fund research organisations and undertakings, as defined by the EC regulation on State aid for research, development and innovation (see the ANR Funding regulations for further reference).</p> <p>As for research organisations, only those that have their primary establishment in France may be funded. As for undertakings, those that have their real head office in an EU member State and having an establishment (primary or secondary) in France may be funded.</p> <p>Within this framework, research institutions such as EPST, EPIC, Universities, Hospitals, most foundations, as well as companies and NGOs (<i>associations</i>) can apply. This list is not comprehensive and funding rates vary. Please fill the form related to economical activities to identify your funding rate and consult the “règlement financier” <a href="http://www.agence-nationale-recherche.fr/RF">http://www.agence-nationale-recherche.fr/RF</a> for more details.</p> <p>Please note that companies with economic difficulties cannot receive ANR subventions.</p>
<b>Eligible costs</b>	Standard ANR funding rules apply for eligible costs. These rules are specified in ANR’s “Règlement financier” mentioned above and in an explanatory note available at: <a href="https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf">https://anr.fr/fileadmin/documents/2017/ANR-RF-Fiche-COUTS.pdf</a>



	Eligible costs (e.g.: personnel costs of non-permanent researchers, costs of instruments and equipment, additional overheads and other operating expenses incurred directly as a result of the research project such as, for instance: travel costs) and funding rates vary based on the type of research and research partner. Please note that expenses related to permanent staff are not eligible for the beneficiaries “à coût marginal”. For the beneficiaries “à coût marginal”, please note that the overheads correspond to 13% of the eligible costs (10.5% dedicated to “tutelle gestionnaire” and 2.5% to the laboratory).
<b>Additional documents required</b>	No additional documents should be submitted to ANR during the submission phase. If a project is selected for funding, French partners will have to fill administrative and financial data on the ANR platform.
<b>Eligible One Health settings</b>	All 3 research areas (Human Health, Animal Health and Plants/environnement) are eligible for funding.
<b>Eligible experimental approaches</b>	All approaches with the exception of phase III clinical trials.
<b>Further information</b>	<p><b>Maximum amount per project:</b> 470 000 €  <b>Maximum funding per partner:</b> 260 000 € (Increased to 310 000 € for coordinators)  <b>Minimum amount per partner:</b> 15 000 €</p> <p>More details for the participation of French partners (“<i>Modalités de participation</i>”) at <a href="https://anr.fr/fileadmin/aap/2022/aap-jpiamr-druid-2022-annexe-fr.pdf">https://anr.fr/fileadmin/aap/2022/aap-jpiamr-druid-2022-annexe-fr.pdf</a>. In case of a conflict of interpretation between the terms and conditions stated in this annex and the “<i>Modalités de participation</i>” and “<i>Règlement financier</i>”, the latter shall prevail.</p> <p><b>Please note that applications (pre-proposals and full proposals) including partners applying for funding from a Swedish funder will be made available upon request after the publication of the funding decision.</b></p>

<b>Germany – DLR Deutsches Zentrum fuer Luft – und Raumfahrt Ev</b>	
<b>Specific National/ Regional rules</b>	<p>Legal bodies:</p> <ul style="list-style-type: none"> <li>• Universities</li> <li>• University hospitals</li> <li>• Non-university research institutes</li> <li>• Industry</li> </ul> <p>Note: industry is funded with a maximum of 50-60% of their costs.</p>
<b>Eligible costs</b>	<p>Personnel, Consumables, Animals, Subcontracts, Equipment, Travel, Overheads refer to “Gemeinkosten” (applicable e.g. for Helmholtzcentres and Fraunhofer-Society) as well as “Projektpauschale” (applicable for universities and university hospitals).</p> <p>Individual project coordinators/partners may request up to 300 000 Euro. A project consisting of two or more German partners may request a maximum of 500 000 Euro.</p> <p>For further details please refer to the national guidelines “<u>BMBF Formularschrank</u>”<sup>1</sup></p>

<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Eligible experimental approaches</b>	All
<b>Further information</b>	For further details please refer to the national guidelines " <a href="#">BMBF Formularschrank</a> " <sup>1</sup>

<b>Hungary– NKFIH National Research, Development and Innovation Office</b>	
<b>Specific National/ Regional rules</b>	Eligible applicants from Hungary are entities falling under any of the following GFO codes: <ul style="list-style-type: none"> <li>• enterprise with legal entity (GFO code: 11X)</li> <li>• non-profit organisation with legal entity (GFO code: 5XX)</li> <li>• budgetary units and entities (e.g. higher education institutions, municipalities;) (GFO code: 3XX)</li> <li>• enterprise with a registered office in the European Economic Area and a branch in Hungary (GFO: 226).</li> </ul>
<b>Eligible costs</b>	All research-related costs in accordance with government decree 380/2014 (XII.31) are eligible. In case a partner is subject to State Aid rules, funding intensity shall be set at a level that complies with the State Aid rules in force at the time of the funding decision.
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	Human health, animal health, environmental health.
<b>Eligible experimental approaches</b>	All
<b>Further information</b>	The Guide for Applicants for the 2019-2.1.7-ERA-NETnational call is applicable: <a href="https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net">https://nkfi.gov.hu/palyazoknak/nkfi-alap/era-net-ejp-cofund-2019-217-era-net/palyazati-felhivas-2019-217-era-net</a>

<b>Israel – CSO-MOH Chief Scientist Office, Ministry of Health</b>	
<b>Specific National/ Regional rules</b>	CSO-MOH (Israel) will only fund proposals with relation to Human Health. PI should hold a Ph.D., M.D., D.M.D., D. Sc or equivalent degree and employed by an eligible institution ( hospitals, clinics, laboratories, academic and public research institutions Research will not be funded simultaneously by CSO-MOH on more than one grant (Era-NET or national). Researchers can not apply for more than one grant from any ERA-NET funded by CSO-MOH or submit more than one proposal for any programme.
<b>Eligible costs</b>	Materials and consumables; Travel (up to 10%); No salaries for applicants; No heavy equipment, Institutional overhead 10%.  Available budget: 0.3M (up to 2 projects. 140K per project + additional 20K per project coordinators)
<b>Additional documents</b>	Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including budget distribution. No submission of

<b>required</b>	abstract can result in declaration of the consortium as ineligible. If the application involves human or animal experiments, bioethics approvals must be submitted with the application or up to 4 months later.
<b>Eligible One Health settings</b>	Human health, Animal health, Environmental health (Only in relation to human health).
<b>Eligible experimental approaches</b>	Standard National Grant Conditions apply
<b>Further information</b>	Please see detailed instructions of application at the national level and reporting at <a href="http://www.health.gov.it/research-fund">http://www.health.gov.it/research-fund</a>

Italy – FRRB Fondazione Regionale per la Ricerca Biomedica	
<b>Specific National/ Regional rules</b>	<p><b>MAXIMUM TWO PARTNERS from Lombardy PER PROJECT</b></p> <p>Eligible applicants:</p> <ul style="list-style-type: none"> <li>• Public or Private Italian IRCCS (Scientific Institutes for Health Research, Hospitalization and Health Care)</li> <li>• Public Health Care Providers (ASST)</li> <li>• Universities (<i>only in in partnership with one IRCCS, public or private, or an ASST located in Lombardy and requesting funding to FRRB</i>)</li> <li>• Research Institutes (<i>only in in partnership with one IRCCS, public or private, or an ASST located in Lombardy and requesting funding to FRRB</i>)</li> </ul> <p>Please note : All applicants must be located in Lombardy and their activities should take place in Lombardy .</p> <p><b>Enterprises and for profit Organisations are NOT eligible.</b></p>
<b>Eligible costs</b>	<p>Direct costs:</p> <ul style="list-style-type: none"> <li>• Personnel (for <b>public</b> IRCCS and ASST, only staff recruited specifically on the project)</li> <li>• Consumables, animals purchase, maintenance and breeding;</li> <li>• Equipment (on hire or eligible amortization rate);</li> <li>• Travel: max 10% of the total direct costs(<i>overheads and subcontracting costs excluded</i>)</li> <li>• Publications (only open access): max 5% of the total direct costs (overheads and subcontracting costs excluded).</li> <li>• Overheads: 20% flat rate calculated on direct costs (Subcontracting costs excluded from this calculation).</li> <li>• Subcontracting: max 20% of the total direct costs (overheads costs excluded)</li> <li>• Other direct costs: please include here other costs, including those related to patient involvement (insurance, reimbursement, ecc).</li> </ul> <p>FRRB will require the submission of a financial audit certificate together with the final financial report. This cost, to be included under the “Subcontracting” category will be eligible up to a maximum of € 8.000.</p> <p>Only costs generated over the lifetime of the project will be considered eligible.</p>

<b>Additional documents required</b>	<p>According to internal procedures, Regional Foundation for Biomedical Research (FRRB) will grant an eligibility clearance to the potential applicants prior to the submission of the pre-proposals.</p> <p>The eligibility check will be based on the verification of a dedicated form ("<i>Eligibility check form</i>"), to be completed by the Principal Investigator at least 10 working days before the pre-proposal submission deadline.</p> <p>FRRB will provide feedback on the "<i>Eligibility check form</i>" ONLY in case of major non-eligibility issues. Informations and instructions on how to fill the <i>Pre-Eligibility check form</i> will be published on the dedicated webpage (<a href="http://www.frrb.it/it/jpiamr-14th-joint-call">http://www.frrb.it/it/jpiamr-14th-joint-call</a>)</p>
<b>Eligible One Health settings</b>	Only Human Health area will be eligible for funding
<b>Eligible experimental approaches</b>	Biomedical research ONLY in human settings. In case of clinical studies, the size and the duration should be compatible with the project timeline- studies should be completed by the end of the project.
<b>Further information</b>	<p>Maximum € 500,000 <b>per project</b> (if there are two Lombardy partners in the same consortium, the amount of 500,000 will be shared)</p> <p><b>A Principal Investigator (PI) cannot simultaneously hold more than one FRRB active grant.</b></p> <p>PIs who are currently FRRB grant holders cannot apply to the JTC DRUID unless their project is closed before the deadline for JTC DRUID pre-proposals. A project is considered closed when the final financial and scientific reports have been sent to FRRB.</p> <p>This rule applies only to PIs (grant holders), not to their team members.</p>

Italy – IT-MOH Italian Ministry of Health	
<b>Specific National/Regional rules</b>	<p>Only Scientific Institutes for Research, Hospitalisation and Healthcare (IRCCS) and Istituto Superiore di Sanità (ISS) are eligible. No academic and industrial partners are eligible.</p> <p>Researchers are not allowed to participate as PI/WP Leader in more than one 2022 call launched in the framework of different transnational calls (ERANET and/or other European Joint Actions- MAECI EPs) funded by the It MoH. MAXIMUM TWO PARTNERS funded by the It-MoH PER PROJECT .</p> <p>Researchers are requested to indicate the IRCCS as unique affiliated Institution and to use exclusively the IRCCS's email.</p>
<b>Eligible costs</b>	<p>Only the costs generated throughout the duration of the project can be eligible.</p> <ol style="list-style-type: none"> <li>1. Personnel (only ad hoc contracts/consultants/fellowships, max 50% of the requested fund);</li> <li>2. Travel costs and subsistence allowances (max 10% of the requested fund);</li> <li>3. Equipment (rent/leasing only, no limits), consumables (no limits), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund);</li> <li>4. Data handling and analysis (no limits);</li> <li>5. Overhead (maximum 10% of the requested fund).</li> <li>6. Travel expenses and subsistence allowances only if associated with training activities linked to the project.</li> </ol> <p>Sub-contracts will not be automatically authorized. Sub-contracts will be evaluated following the sending (alongside the pre-eligibility form,) of a detailed application, and only if absolutely needed. The costs for sub-contracts shall be authorized by the It MoH in advance, following a detailed</p>

	<p>request. In this case, the pre-eligibility must be SENT 20 working days before the deadline of the call.</p> <p>Maximum funding per project: 0.25 M€.</p> <p>In the case that two eligible partners are involved in the Consortium, the total amount will be shared between the beneficiary Institutions.</p>
<b>Additional documents required</b>	The Italian Ministry of Health will check for the pre-eligibility of the applicants before the submission of the pre-proposals to speed up the eligibility check process. To this end, it is mandatory that the applicants fill out and return a pre-eligibility check form (sent to all IRCCSs) through the IRCCS Scientific Directorate or ISS Directorate of Human and Economic Resources using the WFR System (Code ER) before the submission of their pre-proposals to the Joint Call Secretariat. The form, completed and duly signed, has to be returned at least 10 working days before the pre-proposal submission deadline. Applicants will receive a written notification of their eligibility status.
<b>Eligible One Health settings</b>	The Italian Ministry of Health funds ONLY human-related research activities (fundamental clinical research)
<b>Eligible experimental approaches</b>	It MoH component clinical studies are eligible for funding as long as the costs are within the 250.000 € and allowed within the duration of the project.
<b>Further information</b>	<p>The pre-eligibility form can be downloaded here:</p> <p><a href="http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf">http://www.salute.gov.it/imgs/C_17_pagineAree_4441_listaFile_itemName_0_file.pdf</a></p>

<b>Latvia – VIAA/LZP</b> <b>Valsts Izglitības Attīstības Aģentūra - replaced by Latvijas Zinatnes padome from 01.01.2022</b>	
<b>Specific National/ Regional rules</b>	<p>1. Funding of industrial partners is eligible only if they represent business enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. The main activity should be in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements.</p> <p>2. The other category of partner eligible for funding is Research institutions: Universities, research institutes, other research institutions –must be listed mandatory in the Latvian register of scientific institutions. They must comply with Research and knowledge-dissemination organization criteria (R651/2014).</p> <p>Any other type of participants can not be funded.</p>
<b>Eligible costs</b>	<p>Per partner: 100,000 EUR/year, i.e. maximum grant per partner is 300,000 EUR for a 3-year project.</p> <ul style="list-style-type: none"> <li>• Personnel costs incl. taxes;</li> <li>• Consumables;</li> <li>• Subcontracts (up to 25% of direct costs), needs detailed justification, includes all external services, project core activities cannot be subcontracted;</li> <li>• Equipment (only depreciation costs);</li> <li>• Replaceable and fully consumable during project elements of equipment, materials and animals;</li> <li>• Travels (according to travel plan);</li> <li>• Indirect costs (up to 25% of direct costs excluding subcontracting).</li> </ul> <p>Costs must be research and innovation costs, there is no support for other activities</p> <p>Latvia allows max. 2 Latvian partners per proposal. In case of two Latvian partners per proposal, they shall be completely independent entities.</p>
<b>Additional documents</b>	Applicants might be asked to provide additional information in order to assess their eligibility. Applicants are obliged to provide any information specified by

<b>required</b>	Provisions of the Cabinet of ministers No 259, 26.05.2015 upon request. Enterprises shall provide balance sheet and statements for two preceding closed financial years.  To release funding, duly signed Consortium Agreement shall be presented to funding body.
<b>Eligible One Health settings</b>	Human health, animal health, environmental health
<b>Eligible experimental approaches</b>	Experimental work with cells, plants and animals Early stage (PoC) clinical studies No clinical partnerships can be funded
<b>Further information</b>	See Provisions of the Cabinet of Ministers: <a href="http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma">http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibaistarptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma</a> They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET Cofund are an eligibility criteria for funding. Scientific and financial reports should be provided as requested. To release the funding, duly signed Consortium Agreement must be presented.

<b>Lithuania – LMT Research Council of Lithuania</b>	
<b>Specific National/ Regional rules</b>	The proposals are submitted by the researcher(s) together with the eligible beneficiary institution. The beneficiary institution employ the principal investigator to work in the project and his work load must be at least 20 hours multiplied by the number of months to execute the project. Hourly rates approved by the Chairman of the Lithuanian Research Council must be applied for the personnel costs. All other general rules for competitive funding of Research Council of Lithuania apply: <a href="https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr">https://www.e-tar.lt/portal/lt/legalAct/Oa8bead0577611e9975f9c35aedfe438/asr</a>
<b>Eligible applicants</b>	Eligible for funding institutions are Lithuanian research and higher education institutions included in the Register of Education and Research institutions and public healthcare institutions. Beneficiary institution manage the state budget funds allocated to the project following the rules stated in the legal acts, as well as representing the project partners (if applicable 'project partner' means public or private legal entity that, together with the eligible institution, created the conditions for project implementation).
<b>Eligible costs</b>	Only costs generated during the lifetime of the project, related to project are eligible: staff, travel, consumables, subcontracts, contractual research, consultancy, equipment and instruments, dissemination of results, data handling and analysis, overheads (up to 30 % from the listed direct costs - staff, subcontracts, contractual research, consultancy). Max. grant amount 100 000 Eur (per project)
<b>Additional documents required</b>	No
<b>Eligible One Health settings</b>	All

<b>Eligible experimental approaches</b>	<p>All type of studies/ experimental approaches that are eligible to the call:</p> <ul style="list-style-type: none"> <li>• <i>In silico, in vitro, in vivo</i> and/or</li> <li>• Preclinical and clinical studies in human and in all veterinary settings, and/or</li> <li>• Studies in crop/plant settings, including field studies</li> </ul>
<b>Further information</b>	<a href="https://www.lmt.lt/lt/mokslo-finansavimas/era-net-ir-kitos-koordinavimo-veiklos/jpiamr-action/3627">https://www.lmt.lt/lt/mokslo-finansavimas/era-net-ir-kitos-koordinavimo-veiklos/jpiamr-action/3627</a>

<b>Moldova – NARD National Agency for Research and Development</b>	
<b>Specific National/ Regional rules</b>	<p>Eligibility: Research organisations (according to their statute)</p> <p>The proposals are submitted by the researcher(s) together with the eligible beneficiary institution. The principal investigator must be employed by the beneficiary institution for the duration of the project and his work load must not exceed 12 hours per day in all projects financed by ANCD. Remuneration in the project will be based on the national legislation.</p> <p>ANCD will avoid double funding and will not finance projects or part of projects that have been funded through other calls.</p> <p>In Moldova, the projects will be implemented by one MD organisation independent or in partnership with local public or private partners. Thus, for one project proposal the only one public research organisation can request funding.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>- Personnel costs</li> <li>- Travelling</li> <li>- Events</li> <li>- Consumable;</li> <li>- Laboratory equipment</li> <li>- Research papers;</li> <li>- Experimental and production activities.</li> </ul> <p>Maximum requested budget per project – 100.000 EUR</p> <p>Minimum requested budget per project - 60.000 EUR</p>
<b>Additional documents required</b>	<p>The additional documents that should be submitted to ANCD during the submission phase are published in the call announcement at the ANCD website. In case a project is selected for funding, Moldovan partners will be invited to sign grant contracts. Successful MD project partners will have two month from the date they are notified of a positive funding decision to submit the grant contract completed.</p> <p><b>Reporting</b></p> <p>In addition to reporting requirements set out in the call document, standard ANCD reporting terms and conditions will apply. MD partners are expected to report on outputs and outcomes on a regular basis.</p>
<b>Eligible One Health settings</b>	Human health, animal health, environmental health
<b>Eligible experimental approaches</b>	<i>in silico, in vitro, in vivo</i> studies, pre-clinical and clinical studies, studies in crop/plant settings
<b>Further information</b>	<p><b>Vadim Iatchevici</b> +373 22 270-445 <a href="mailto:vadim.iatchevici@ancd.gov.md">vadim.iatchevici@ancd.gov.md</a></p>

	Official website: <a href="https://anecd.gov.md/ro">https://anecd.gov.md/ro</a>
--	---

<b>Poland – NCN National Science Centre</b>	
<b>Specific National/ Regional rules</b>	<p>National rules for participation are given in the <a href="#">UNISONO resolution no. 80/2021 of 9 September 2021</a></p> <p>Please note:</p> <ul style="list-style-type: none"> <li>project tasks to be carried out by Polish research teams may involve <b>only basic research</b> i.e. experimental or theoretical endeavours undertaken to gain new knowledge of the foundations of phenomena and observable facts, without any direct commercial use;</li> <li>proposals may include application for <a href="#">state aid</a>, except where a natural person applies for funding;</li> <li>proposals may involve non-commercial clinical trials related to a medicinal product or a medical device;</li> </ul> <p>NCN funds projects that last either 24 or 36 months.</p>
<b>Eligible costs</b>	<p>All costs relevant, necessary and directly connected to the proposed research project including:</p> <ol style="list-style-type: none"> <li><b>Personnel costs</b> – permanent and/or temporary; including post-doc positions and scholarships for PhD students;</li> <li><b>Equipment</b>: up to 110 018 EUR (500,000 PLN) per unit;</li> <li><b>Other direct costs</b>: materials, devices and software, outsourcing and subcontracting, travel and subsistence costs, visits and consultations, costs of publications, collective investigators;</li> <li><b>Overheads/indirect costs</b>: there are two types of indirect costs, both calculated automatically: <ul style="list-style-type: none"> <li>indirect costs of Open Access (publications and data) - up to 2% of total direct costs of the project</li> <li>other indirect costs - up to 20% of total direct costs of the project. General indirect costs include administrative personnel costs as well as costs of organizing conferences, workshops, seminars or meetings.</li> </ul> </li> </ol> <p>The amount budgeted for indirect costs may not be increased during the course of a research project.</p>
<b>Additional documents required</b>	<p>At the full proposal stage, Polish applicants must submit their national proposals in the Polish submission system (ZSUN/OSF). Polish national proposals must state the budgets in Polish currency using the conversion rate of <b>1 EUR = 4,5447 PLN</b>.</p> <p>If two or more different Polish institutions apply as partners within one international project consortium and seek funding from the NCN, they must apply to the NCN as a group of entities.</p>
<b>Eligible One Health settings</b>	<ul style="list-style-type: none"> <li>Human health, and/or</li> <li>Animal health (including wild-life, livestock, fishes, and companion animals), and/or</li> <li>Plants (including trees and crops)</li> </ul>
<b>Eligible experimental approaches</b>	<ul style="list-style-type: none"> <li><i>in silico, in vitro, in vivo</i> and/or</li> <li>preclinical and clinical studies in human and in all veterinary settings, and/or</li> <li>Studies in crop/plant settings, including field studies</li> </ul>
<b>Further information</b>	<ul style="list-style-type: none"> <li><a href="#">NCN Open Access Policy</a></li> <li><a href="#">Information about Personal Data Processing at NCN</a></li> </ul>



Poland – NCBR National Centre for Research and Development	
Specific National/ Regional rules	<p>Following entities are eligible to apply:</p> <ul style="list-style-type: none"> <li>• Micro, Small, Medium and Large Enterprise;</li> <li>• Research organization;</li> </ul> <p>Organization must be registered in Poland. For enterprises it is strongly advised to state in the Pre-proposal application form the KRS number of the enterprise and the size of the enterprise (micro/small, medium, large).</p> <p>Budget limit - up to 200 000 EUR per project, regardless of the number of Polish research groups in the project consortium.</p> <p>In addition, if two Polish participants take part in the project, they must form an internal national consortium to sign the contract with the National Centre for Research and Development (NCBR). The above consortium should be created on the day of signing the contract with NCBR at the latest. The Polish consortium still counts as two project partners from Poland.</p>
Eligible costs	<p>The eligible costs shall be the following:</p> <ol style="list-style-type: none"> <li>1. <b>personnel costs</b> (researchers, technicians and other supporting staff to the extent employed on the research project);</li> <li>2. <b>operating costs</b> including costs of instruments, equipment, technical knowledge, patents, costs for buildings and land, costs of materials, supplies and similar products incurred directly as a result of the research activity;</li> <li>3. <b>cost of contractual research</b>, costs of consultancy and equivalent services used exclusively for the research activity; this cost type cannot account for more than 70% of all eligible costs of a project; the subcontracting can be obtained from consortium partner only in justified case, this need will be verified by a national experts panel;</li> <li>4. <b>additional overheads</b> incurred indirectly as a result of the research project; that costs cannot account for more than <b>25%</b> of eligible project costs and are counted as a multiplication by percentage given above and the rest of direct costs, excluding subcontracting (<b>3</b>); It means <math>4=(1+2)*25\%</math>.</li> </ol> <p>Funding quota of Polish participants can be up to 100% for universities or research organizations. In the case of enterprises, funding quota will be decided on a case-by-case basis depending on the size of the company, type of research/development, risk associated with the research activities and commercial perspective of exploitation, under the Regulation of the Minister of Science and Higher Education of 19 August 2020 on criteria and rules on granting state aid by the National Centre for Research and Development, published in Journal of Laws item 1456, 2020.</p>

		<b>Large Enterprises</b>	<b>Medium Enterprises</b>	<b>Small Enterprises</b>	<b>Universities and research organizations</b>
	<b>Fundamental / Basic Research</b>	Not eligible	Not eligible	Not eligible	Not eligible
	<b>Industrial / Applied Research</b>	Up to 50+15 (max 65 %)	Up to 50+10+15 (max 75 %)	Up to 50+20+15 (max 80 %)	Up to 100 %
	<b>Experimental development</b>	Up to 25+15 (max 40 %)	Up to 25+10+15 (max 50 %)	Up to 25+20+15 (max 60 %)	Up to 100 %
	Only Industrial/Applied Research and Experimental Development will be funded. Other type of activities (e.g. coordination, dissemination, management) is not eligible for funding as separate research tasks in the project schedule.				
<b>Additional documents required</b>	Polish Participants will be informed and invited to submit Polish proposal once the international evaluation and the ranking list will be established.				
<b>Eligible One Health settings</b>	No additional limitations				
<b>Eligible experimental approaches</b>	No additional limitations				
<b>Further information</b>	No additional limitations				

<b>Spain – AEI Agencia Estatal de Investigación</b>	
<b>Specific National/ Regional rules</b>	<p>The eligible entities for the AEI funding are:</p> <p>Non-profit research organizations (such as universities, public research institutions, technological centres and other private non-profit institutions performing RDI activities in Spain), as per PCI 2020-1 call. They must have been previously beneficiaries of any of the AEI calls. They have to ensure contractual relationship with the Principal Investigator during all the time of development of the project.</p> <p>Although private companies are not funded by the AEI, the Spanish industrial sector is welcome to participate in the transnational consortia using their own funds or obtaining funds from the CDTI or other innovation and technological development funding agencies.</p> <p>Mandatory:</p> <p>The Spanish Principal Investigators (PIs) must hold a PhD degree. It applies to all the members of the research team.</p> <p>PIs must be eligible according to PCI 2021 call and must have experience as investigators (not necessarily as PIs) in projects funded by the Plan Nacional I+D+i 2008-2011, the Plan Estatal I+D+i 2013-2016, the Plan Estatal I+D+i 2017-2020, ERC Grants, European Framework Programmes or other relevant international programmes.</p>

	<p>Incompatibilities (these must be taken into account when participating in different ERA-Nets or other international initiatives):</p> <ul style="list-style-type: none"> <li>• PIs will not be eligible for funding if they apply as PIs to more than one proposal in this transnational joint call, to more than one proposal in the same Spanish PCI call and/or to PCI calls of consecutive years.</li> <li>• If the same PI submits two or more proposals to the present call, all but one will be declared ineligible, without the possibility of changing the IP.</li> <li>• A researcher that has been granted a PCI as PI the previous year will be declared ineligible as PI in the present call, without the possibility of changing the IP.</li> <li>• PIs must remain unchanged between the proposal of this transnational joint call and the national PCI call.</li> </ul> <p>The AEI will avoid double funding and will not grant projects or parts of projects already funded through other national or EU calls.</p> <p><b>Only justified changes</b> will be allowed between phase 1 and 2.</p> <p>Failure to respect the requirements will lead to the ineligibility of the proposal.</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>• Only personnel costs for new temporary employment contracts are eligible. The costs of permanent staff linked to the beneficiary entity or members of the research team will not be considered eligible costs.</li> <li>• Direct costs such as current costs, small scientific equipment, disposable materials, travelling expenses, coordination costs, and other costs that can be justified as necessary to carry out the proposed activities. VAT could be non eligible, depending on the application of RRF funds.</li> <li>• Indirect costs (overheads ) are eligible costs (maximum 15% of direct costs, including outsourcing).</li> <li>• Clinical trials are eligible up to phase 1, with a maximum of 50% of the total budget (contact the National Contact Point for further details)</li> <li>• Subcontracting should not exceed 25% of total final budget (excluding overheads).</li> </ul> <p>The following <b>funding limits (including direct + indirect costs)</b> are considered eligibility criteria. Proposals not respecting these limits could be declared ineligible:</p> <ul style="list-style-type: none"> <li>• If the Consortium is NOT LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>• there is only one Spanish Partner in the proposal: € 200.000.</li> <li>• there are two Spanish Partners in the proposal, the amount for both Partners is: € 250.000</li> </ul> </li> <li>• If the Consortium IS LED by a Spanish Coordinator and: <ul style="list-style-type: none"> <li>• there is only one Spanish Partner in the proposal acting as Coordinator: € 300.000</li> <li>• there are two Spanish Partners in the proposal and one is acting as Coordinator, the amount for both Partners is: € 350.000</li> </ul> </li> </ul> <p>IMPORTANT: A maximum of two Spanish Partners requesting funding to the AEI in the same proposal are allowed.</p> <p>Centers formed by different Spanish legal entities will be considered as a unique entity, and thus the maximum funding should not exceed the limits per proposal established above (for example, mixed centers).</p>

	The final funding will take into account the transnational evaluation of the collaborative proposal, the scientific quality of the Spanish group, the added value of the international collaboration, and the financial resources available.
<b>Additional documents required</b>	It is highly recommended to include the PI's full name and identification number as they appear in the DNI at the beginning of the proposal
<b>Eligible One Health settings</b>	The three of them
<b>Eligible experimental approaches</b>	Clinical trials are eligible up to phase 1 (please contact the national contact point for further details)
<b>Further information</b>	<p><b>Funding Programme:</b> The framework for this funding action is the <i>Plan Estatal de Investigación Científica, Técnica e Innovación 2021-2023</i>. On a national level, the Call will be managed by the <i>Subdivisión de Programas Científico-Técnicos Transversales, Fortalecimiento y Excelencia</i> (STRAN) of the AEI.</p> <p><b>Instrument for funding the Spanish groups</b> The instrument for funding the Spanish groups is the Spanish call on International Collaboration Projects (PCI)". Please take <a href="#">PCI2021-2</a> as reference. <b>The general requirements of PCI will apply.</b> Applicants should abide by these general requirements and are encouraged to carefully read the call.</p> <p><b>Acknowledgement:</b> Any publication or dissemination activity resulting from the granted projects <u>must</u> acknowledge funding by the Agencia Estatal de Investigación: "Project (reference nº XX) funded by the Agencia Estatal de Investigación through the PCI (year) call".</p> <p><b>Data Protection:</b> By submitting a grant application to the AEI, the applicants consent to communication of the data contained in the application to other public administrations, with the aim of further processing of the data for historical, statistical or scientific purposes, within the framework of the Organic Law 3/2018, of December 5, on Personal Data Protection and Guarantee of Digital Rights.</p>

Spain – ISCIII National Institute of Health Carlos III	
<b>Specific National/ Regional rules</b>	<p><b>Funding Program:</b> Acción Estratégica en Salud (AES)  <b>Initial funding pre-commitment:</b> 1.000.000 €  <b>Number of groups</b> that could be funded: 4-6  <b>Maximum grant duration:</b> 36 months  <b>Maximum funding per awarded Spanish project partner:</b>  7. Up to 175.000 € per partner (overheads included)  8. Up to 250.000 € per coordinator (overheads included)</p> <p><b>Eligible institutions:</b></p> <ul style="list-style-type: none"> <li>• <b>Accredited Health Research Institutes</b> (Institutos de Investigación Sanitaria Acreditados, IIS). Accredited according to the RD 339/2004, of February 27th or RD 279/2016. (These institutions may manage research via a foundation regulated according to the Spanish Act 50/ 2002, of December 26th). See the list of IIS in <a href="#">this link</a>.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Hospitals, primary health care or public health administration of the Spanish National Health System (SNS).</b> These institutions may manage research via a foundation regulated in accordance to the Spanish Act 50/2002, of December 26th (a copy of the foundation's statutes may be submitted).</li> <li>• <b>CIBER.</b> Team members applying to the call must be from at least two groups belonging to CIBER in two different home institutions and one of these two must be a Hospital, primary health care or public health administration of the Spanish National Health System (<b>SNS</b>) or <b>IIS</b>. Please contact Cristina Rodríguez (<a href="mailto:crisrina.rodriguez@ciberisciii.es">crisrina.rodriguez@ciberisciii.es</a>) for more information related to CIBER's eligibility.</li> <li>• <b>Academia or Other Research Centers</b> (public or private non-for profit). These entities can <b>only</b> participate if they apply together with Hospitals, primary health care or public health settings of the <b>SNS</b> or <b>IIS</b> in the same proposal. It is not allowed to apply independently, thus <b>there must be two beneficiary Spanish institutions requesting funding to ISCIII in the same proposal.</b></li> </ul> <p><b>Please Note:</b></p> <ol style="list-style-type: none"> <li>9. Applicants from ISCIII are eligible. Eligibility criteria from AESI 2022 apply</li> <li>10. Same institution cannot participate with more than one partner in the same project proposal.</li> <li>11. Only one PI per beneficiary institution may be funded within the same proposal.</li> <li>12. A given PI can apply only once to this call.</li> <li>13. PIs with ongoing projects in 2023 funded in a JPI AMR call are not eligible for funding by ISCIII in the current call unless the ongoing project or the new application is as coordinator.</li> <li>14. There is no other incompatibility with AES 2022.</li> <li>15. Incompatibility for application to any other call are subject to the provisions in the relevant call.</li> <li>16. SMEs and other private companies are encouraged to participate at their own cost, as subcontractors.</li> </ol> <p><b>Eligibility of PI and team members</b></p> <ul style="list-style-type: none"> <li>• Principal Investigators (PIs) can only participate in one project proposal per call.</li> <li>• Principal Investigators (PIs) belonging to any IIS could apply only from the IIS or from any of the institutions belonging to the IIS.</li> <li>• The Principal Investigator (PI) and all members of the research group must belong to the eligible institution or be affiliated to CIBER or an IIS</li> </ul> <p><b>Excluded</b> personnel as Principal Investigator (PI):</p> <ul style="list-style-type: none"> <li>• Those undergoing a postgraduate training in Health Specialization (MIR, EIR, FIR, QIR, BIR, PIR, RFIR).</li> <li>• Those undergoing research training (e.g. PhD students, or "Río Hortega" contracts).</li> <li>• Researchers contracted by a RETIC/RICOR.</li> </ul> <p>Those undergoing postdoctoral training (e.g. "Sara Borrell" or "Juan de la Cierva" contracts).</p>
<b>Eligible costs</b>	<ul style="list-style-type: none"> <li>• Personnel costs for temporary employment contracts (scholarships are not eligible) with a maximum of 36 PM in total for the personnel contracts altogether.</li> <li>• Current costs, small scientific equipment, consumables, disposable materials, traveling expenses and other costs as included in AES 2022 that can be justified as necessary to carry out the proposed activities.</li> </ul>

	<ul style="list-style-type: none"> <li>Overheads: up 21% of the direct (according to AES 2022)</li> </ul> <p>Double funding of the same concept is not allowed.</p>
<b>Additional documents required</b>	
<b>Eligible One Health settings</b>	Human health. Animal health could be funded by ISCIII if the proposal is related with zoonotic diseases. Environment can only be funded if it has direct connection with human health.
<b>Eligible experimental approaches</b>	Spanish groups participating in a proposal performing a clinical study are encouraged to contact and include as members of the team personnel from the Clinical Trial Unit (Unidades de Investigación Clínica y Ensayos Clínicos - UICEC) belonging to the Clinical Research Supporting Platform of their institutions, the scientific node of the EU Clinical Trials Network.
<b>Further information</b>	<p><b>Additional requirements on data and repositories</b></p> <ul style="list-style-type: none"> <li>Researchers funded by ISCIII must make public the human genomic data, as well as relevant data (phenotype and exposition data) generated inside the funded project and will use open access repositories. Researchers must also make public all the necessary information for the interpretation of these genomic data, including lab protocols, data instruments survey tools. Regarding genomic data it is understood: association of complete genomes (GWAS), matrixes of de polymorphism of a single nucleotide (SNP) and sequence of genome, and transcriptomic, metagenomic, epigenomic and gene expression data. The researchers whose projects are funded by ISCIII are recommended to store their scientific data at the "<a href="#">ELIXIR Core Data Resources</a>", or if non-European repositories or data bases are to be used they must be certified by ELIXIR or the US National Center for Biotechnology Information (NCBI).</li> <li>ISCIII may not fund any project that may require a repository and/or a data base without a plan ensuring sustainability and decommissioning after the end of funding.</li> </ul> <p><b>Acknowledgements</b></p> <p>Any publication, data base, product or event protected with IPR or not, resulting from the granted project must acknowledge "Award no. XX by Instituto de Salud Carlos III (ISCIII) thorough AES 2022 and within the JPND framework" even after the end of the project. For more information please see ISCIII's ROR <a href="#">here</a>.</p> <p><b>National phase</b></p> <ul style="list-style-type: none"> <li>National applications will be required by ISCIII. Spanish Applicants should periodically check in the web page of ISCIII if they are qualified. ISCIII may not send invitations to the mandatory national phase.</li> </ul> <p>Due to administrative and legal regulations, the Institute of Health Carlos III establishes the national deadline for the decision on fundable project consortia which includes Spanish partners to be funded by ISCIII according to the National application period stated in AES 2022. Any concerned applicant in a proposal for which no final decision has been made by the deadline, could be declared not fundable by ISCIII.</p>

Sweden – Sida Swedish International Development Cooperation Agency	
<b>Specific National/Regional rules</b>	<b>Eligible institutions:</b> Sida will support the participation of researchers from low-income countries in sub-Saharan Africa (DAC List of ODA Recipients), and other sub-Saharan African countries where Sweden has bilateral development cooperation.

	<p>Institutions eligible to apply are Africa-based domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the following countries:</p> <p><b>Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros, Congo (Dem. Rep.), Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Senegal, Sierra Leone, Somalia, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe</b></p> <p>Profit-making organizations are <b>not</b> eligible to receive Sida funding within this initiative.</p> <p><b>Eligible applicants:</b> African researchers employed by domestic universities or other academic research institutions, including non-profit organizations and international organizations, in the countries specified above are eligible to apply.</p> <p>Researchers from profit-making organizations are <b>not</b> eligible to receive Sida funding within this initiative.</p> <p>Researchers may only be listed as a project coordinator or research partner on <b>one</b> project application. However, multiple submissions from multiple projects with researchers based at the same institution are allowed.</p>
<b>Eligible costs</b>	<p>Eligible costs include salaries, consumables, equipment, travel and indirect costs. The use of Sida funds to purchase vehicles, including motorbikes, is not permitted in the frame of this call. Requests for funding for equipment should be accompanied by a plan for the maintenance and repair of the equipment for the duration of the project.</p> <p>Grant funds may not be used to reimburse expenses incurred prior to the project start date.</p> <p>Sida will not fund projects or parts of projects that have been funded through other calls.</p> <p>No grantee is permitted to make sub-grants, but all grantees will be permitted to contract for services, up to a maximum of 20.000 Euro. Please be aware that this limit applies to funds paid by an awardee to any other organization (or an individual employed at another organization) as a subcontractor.</p> <p>Maximum budget per Sida partner is <b>250.000 Euro</b>, and up to <b>350.000 Euro</b> if the Sida partner is the coordinator of a proposal. A maximum of 2 partners eligible for Sida funding may request funding from Sida within a consortium.</p>
<b>Additional documents required</b>	<p>Grants to project coordinators/partners funded by Sida can only be administered by a university or other academic research institution.</p> <p>General conditions applicable to grants from Sida to NGO:s regarding project/programme support will apply to all institutions considered for a grant (<b>document accessible through the call webpage</b>).</p> <p>Before, deciding on grant funding, the capacity of each applicant's institution to administrate funds will be assessed according to Sidas regulations for contribution management, and the projects' adherence to the Swedish strategy for research cooperation and research in development cooperation.</p>

<b>Eligible One Health settings</b>	Human health, animal health and environmental health
<b>Eligible experimental approaches</b>	All
<b>Further information</b>	<p>For the purpose of grant management, Sida will partner with a regional organization experienced in forwarding funding to African universities and research institutes.</p> <p>Individuals that are members of projects invited to make a full proposal may be required to submit additional information that pertains to their specific work and/or budget within the research consortium to Sida, or a designated partner organization.</p>

<b>Sweden – SRC Swedish Research Council</b>	
<b>Specific National/ Regional rules</b>	<ul style="list-style-type: none"> <li>• The applicant must be an individual researcher holding a PhD. Only researchers at an administrating organisation approved by the Swedish Research Council may apply. Please refer to general applicant eligibility requirements found <a href="#">here</a>.</li> <li>• The applicant may not have an ongoing JPIAMR project grant, or any other project grant concerning the same project concept, funded by the Council, at the start of the grant period.</li> <li>• All Swedish applicants are encouraged to communicate with the JPIAMR national contact person regarding their intention to participate in the call, before submission of the consortium application.</li> <li>• Grant amount: Max. 3 500 000 SEK (approx. 345 000 Euro) per consortium with max 2 Swedish partners. Min. 118 000 EUR per partner. Max 5 000 000 SEK (approx. 493 000 Euro) if a Swedish participant is the coordinator of the consortium. No funding of industrial partners. Use the exchange rate of 1 Euro = 10,14 SEK to calculate actual grant amounts for the application.</li> <li>• You can only take part in one consortium within this call, either as coordinator or partner.</li> <li>• All Swedish project leaders participating in the call for support from the Swedish Research Council shall also submit a parallel application using the Swedish Research Council's application system Prisma. The application form in Prisma can be reached from the national call text at the SRC website.</li> </ul> <p><b>Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to the Swedish Research Council before the deadline of the Prisma call may result in the Swedish partner being declared ineligible.</b></p>
<b>Eligible costs</b>	<p>The project grant may be used to fund all types of project-related costs, such as salaries (including your own salary, however no more than corresponding to the person's activity level in the project), running costs (such as consumables, travel including stays at research facilities, publication costs and minor equipment), premises and depreciation costs.</p> <p>Grants may not be used for scholarships. If a doctoral student participates, project funds may not be paid out as salary during teaching or other departmental duties.</p>
<b>Additional documents</b>	A parallel application must be submitted in the SRC's application system Prisma. See above.



<b>required</b>	
<b>Eligible One Health settings</b>	Human health, animal health, plants.
<b>Eligible experimental approaches</b>	No particular conditions.
<b>Further information</b>	See national call texts in <a href="#">Swedish</a> and <a href="#">English</a> for all national requirements.

Sweden– Vinnova The Sweden's innovation agency	
<b>Specific National/ Regional rules</b>	<p><b>The Swedish participation applying for funding from Vinnova should have at least one partner from industry (large companies, small and medium sized companies).</b> Eligible partners are universities, public research institutes, healthcare providers and industry.</p> <p>For more information see the Vinnova web page <a href="#">Find the right funding   Vinnova</a></p> <p>The maximum amount of funding for Swedish participation is: 3 million SEK (approx. 0.3 M€) for 1 Swedish partner in a consortium and 4,5 million SEK (approx. 0.45 M€) for 2 Swedish partners in a consortium. <b>The consortia need to include at least one Swedish partner from industry when applying for funding from Vinnova.</b></p> <p>Universities, public research institutes and public healthcare providers may receive funding of up to 100 % of their eligible costs, provided that the project is part of their non-economic activities. Large companies can apply for 20 % of their eligible costs. Small and medium sized companies can apply for 70 % of their eligible costs. The eligible cost are defined in: <a href="#">Terms and conditions for Vinnova funding   Vinnova</a></p> <p>Swedish applicants must also apply via the Vinnova web portal (<a href="#">Find the right funding   Vinnova</a>), where the Swedish project partner/s should add the requested information and upload the JPIAMR DRUID call project plan. Please follow the instructions on the national call page. Parallel application is a mandatory eligibility criterion. Failure to submit the parallel application to Vinnova before the deadline in the Vinnova portal may result in the Swedish partner being declared ineligible.</p> <p>If you have any questions don't hesitate to email or call one of the Vinnova contact persons. All Swedish applicants are encouraged to communicate with the JPIAMR national contact person regarding their intention to participate in the call before submission of the consortium application.</p>
<b>Eligible costs</b>	The eligible cost are defined in: <a href="#">Terms and conditions for Vinnova funding   Vinnova.</a>
<b>Additional documents required</b>	
<b>Eligible One Health settings</b>	Human health, animal health and environmental health

<b>Eligible experimental approaches</b>	See the Vinnova web page <a href="#">Find the right funding   Vinnova</a>
<b>Further information</b>	See the Vinnova web page <a href="#">Find the right funding   Vinnova</a>

<b>Switzerland – SNSF Swiss National Research Foundation</b>	
<b>Specific National/Regional rules</b>	<p>Projects must comply with SNSF Project Funding regulations and practices:</p> <ul style="list-style-type: none"> <li>• <a href="#">SNSF Funding regulations</a></li> <li>• <a href="#">SNSF Project Funding regulations</a></li> <li>• <a href="#">General implementation regulations for the Funding Regulations</a></li> </ul> <p>In particular, all Swiss based applicants and co-applicants seeking SNSF support must be eligible for SNSF Project Funding. Please note that applications submitted by a non-eligible person will not be considered nor evaluated. Please refer to the regulations and contact the national contact person for questions and re-assurance.</p> <p>Article 7.3 of the Regulations on project funding applies. Swiss based applicants may participate in at most one DRUID proposal.</p> <p>Partners of the international project consortium applying for funding at other funding agencies than the SNSF cannot be declared as project partners in the sense of article 11.2 of the SNSF Funding Regulations. They should be declared as consortium partners instead and apply for their funding at their respective research funding organisation.</p> <p>Article 17 of the SNSF Funding Regulations only applies in the sense that proposals with overlapping funding periods are only approved if the research projects pursue different goals in the context of this European programme than any ongoing projects by the same applicant.</p> <p>Grants will be managed according to standard SNSF rules. Yearly financial reports for the use of SNSF funds and a scientific report at the end of the project will be required.</p>
<b>Eligible costs</b>	<p>According to the <a href="#">regulations on project funding</a> (article 8).</p> <p><b>Overhead contributions cannot be applied for.</b> They are calculated on the basis of the total research funding given to a particular institution through all SNSF funding instruments, are paid directly to the applicant's institution on a yearly basis.</p> <p>The SNSF exclusively funds research conducted for purposes that are not directly commercial. Pursuant to the Research and Innovation Promotion Act RIPA and the legal framework of the SNSF, no research grants are awarded if the relevant research is conducted for directly commercial purposes or if the persons involved in the research work are not scientifically independent.</p>
<b>Additional documents required</b>	<p>Swiss based partners must provide basic administrative data by submitting administrative applications via the online submission system mySNF for the same deadlines as the consortium applications. For this, Swiss based partners need a personal account on <a href="http://www.mysnf.ch">www.mysnf.ch</a>.</p>

	<p>Please select the “Programmes (national and international)-&gt;Partnerships-&gt;JPI AMR” funding instrument when creating the administrative application for the pre-proposal and if you are invited to submit a proposal for the second stage. The pre-proposal can be used as a template when the full proposal is created in mySNF and should be referred to in the section “Relation to pre-proposal” of the full proposal.</p> <p>In case of funding, consortia including Swiss partners must submit a data management plan (DMP) on mySNF which complies with the <a href="#">SNSF policy on open research data</a>.</p>
<b>Eligible One Health settings</b>	All One Health settings including humans, animals, plants, and the environment
<b>Eligible experimental approaches</b>	No additional limitations
<b>Further information</b>	<p>The SNSF earmarked a budget in order to finance approximately 2-3 projects with applicants from Switzerland. To provide for a greater degree of flexibility, there is no maximum contribution set per project for the Swiss part. Nevertheless, budgets of a collaborative research project must be balanced and the SNSF expects that applicants carefully consider the budgetary request in a relation to the effective needs of the project. If an international project includes more than one Swiss based applicant (Principal Investigator), then these applicants must apply together as a consortium and submit a joint budget.</p>

<b>United Kingdom – UKRI</b> <b>United Kingdom Research and Innovation</b>	
<b>Specific National/Regional rules</b>	<p>Awards will be made through MRC on behalf of three UKRI Councils: MRC, BBSRC and EPSRC. Potential applicants are strongly advised to contact the National Call Secretariat, or the UK National contact as detailed in Annex A of the Call, in advance of making an application, to resolve any eligibility queries.</p> <ul style="list-style-type: none"> <li>• Applicants must be a UK based Higher Education Institution, Research Organisation or NHS body, eligible to receive UKRI funding. Industrial partners may not request costs. Full details of eligibility for Research Council funding can be found on the UKRI website: <a href="https://www.ukri.org/funding/how-to-apply/eligibility/">https://www.ukri.org/funding/how-to-apply/eligibility/</a></li> <li>• Please see the UKRI Guidance for Applicants for full information of eligibility and resourcing of grants <a href="https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/">https://www.ukri.org/apply-for-funding/before-you-apply/how-to-apply-for-research-and-innovation-funding/</a></li> <li>• For the purposes of this call, a ‘partner’ requesting funding from UKRI is a legal entity. Multiple researchers from the same legal entity form a single partner, but only one of these researchers should be named on the JPIAMR application form.</li> <li>• Subject to conditions of eligibility and peer review being fully met, up to €1.8M will be available to UK researchers for this call. UKRI anticipate supporting at least 8 applications. Individual consortia may request up to a maximum of €300 000 UK funding, per application. UK-based applicants requesting up to the maximum are welcome, but we also welcome applications requesting under €100 000, to maximise the number of transnational consortia that can be funded.</li> <li>• Once the highest scoring projects have been funded, the remaining UKRI funds may be allocated to projects scoring lower than projects requesting more than the remaining funds available.</li> </ul>

	<ul style="list-style-type: none"> <li>Applicants who intend to collaborate with industrial or other non-academic partners should note that any costs incurred, direct or otherwise, by these partners cannot be met by UKRI Research Councils. Costs incurred by the UK academic partner as a direct result of working with other consortium partners (such as visits to labs or exchange of materials) can be requested. All applications involving industrial partners should complete an MRC Industry Collaboration Agreement (MICA) form, available here: <a href="https://www.ukri.org/councils/mrc/guidance-for-applicants/types-of-funding-we-offer/mrc-industry-collaboration-agreement/">https://www.ukri.org/councils/mrc/guidance-for-applicants/types-of-funding-we-offer/mrc-industry-collaboration-agreement/</a>.</li> <li>The UK component of applications should use full economic costings (fEC). The total amount requested must be 80% fEC. The submitting organisations must agree to find the balance of fEC for the project from other resources. In the 'financial plan' section of the JPIAMR application form, the 'sum requested' is the 80% fEC amount. The 'total' is the 100% fEC amount plus any further resources.</li> <li>Successful UK partners in transnational consortia will be required to upload a single application to Je-S within one month of the notice of award. This must replicate the UKRI component of the JPIAMR application and will not be peer-reviewed. A single UKRI award will be issued to all UK partners within a consortium. The UK partners must therefore identify which researcher is the lead UK applicant, who will be responsible for submitting the Je-S application and whose institution will be responsible for disbursing UKRI funds to any other UKRI-funded partners.</li> <li>Awards are subject to <a href="#">UKRI Terms and Conditions</a> for funding. Award letters will include any additional terms and conditions specific to the call. A fully signed copy of the project Consortium Agreement must be returned to UKRI within six months of award.</li> </ul>
<b>Eligible costs</b>	<p>Eligible costs include project-related costs incurred after the award start date, including:</p> <ul style="list-style-type: none"> <li>Principal Investigators and Co-Investigators time</li> <li>Research and technical staff</li> <li>Estates and Indirect costs</li> <li>Animal costs</li> <li>Travel and Subsistence</li> <li>Equipment</li> <li>Consumables</li> <li>Recruitment and advertising costs for staff directly employed on the project</li> <li>Costs related to research data management</li> <li>NHS Research costs.</li> </ul> <p>Ineligible costs include:</p> <ul style="list-style-type: none"> <li>NHS support and NHS treatment costs</li> <li>PhD students</li> <li>Publication costs</li> <li>Industrial partners.</li> </ul> <p>For more information regarding eligible costs, please see the <a href="#">MRC Guidance for Applicants</a></p>
<b>Additional documents required</b>	<p>As well as the JPIAMR application form, applicants must also complete a UK Budget Proforma.</p> <p>Costs should be included in pounds sterling (GBP) on the UK budget proforma (which can be downloaded from the call entry in the Funding Finder on UKRI's website) and included on the JPIAMR application form in Euros using an exchange rate of £1:€1.15. Applicants should include a statement on the UK</p>

	<p>budget proforma to confirm the exchange rate used, and that costs are entered at 80% FEC according to standard Research Council funding policy.</p> <p>Applications that incur excess treatment costs for studies involving patients will be required to complete a SoECAT form if invited for a full application. Please see the <a href="#">MRC Guidance for Applicants</a> for further information.</p>
<b>Eligible One Health settings</b>	<p>UKRI is unable to support all research areas within the scope of this call because only MRC, BBSRC and EPSRC are contributing funds.</p> <p>For this call, UKRI is unable to support applications where the UK research component relates to wild animals or wild plants.</p> <p>Applications with a major focus on arts, humanities and social sciences approaches, or the natural environment will not be eligible for funding.</p>
<b>Eligible experimental approaches</b>	<p>All experimental approaches, including in vitro, in silico and in vivo pre-clinical, phase I or IIa clinical trials are eligible for funding.</p>
<b>Further information</b>	<p>For further details please refer to the <a href="#">MRC Guidance for Applicants</a></p>